Archive for the ‘Gene Therapy Research’ Category

VANCOUVER, B.C., Sept. 14, 2020 /PRNewswire/ -- The Global Femtech Marketis expected to reach USD 60.01 Billion by 2027, according to a new report by Emergen Research. Demand for the femtech industry is motivated mainly by the growing burden of both chronic and infectious diseases among the world's female population. An increase in the number of health problems relating to women would stimulate competition for technologically innovative healthcare solutions. Growing women's emphasis on reproductive health and sexual empowerment in developing economies would further encourage development in the industry.

Increasing awareness among women of the detection and management of early illness as part of the patient care program would improve the market outlook. Various efforts by government and other agencies in developing countries to raise awareness of women's health would accelerate the development of the industry. Furthermore, an increasing tendency towards daily preventive care check-ups, as well as the advancement of user-friendly technology to track individual health problems, may prove beneficial to the developments in the women's health industry.

While more and more people today choose to be more transparent about their health concerns and treatment, in some of the lesser developed regions, women's health issues remain stigmatized. For these places, Femtech applications are likely to be favored because the scanning is less invasive and more secure. Increasing population growth is related to being one of the main factors behind the case.

Request free sample of this research report at: https://www.emergenresearch.com/request-sample/37

Key Highlights From The Report

Read more at: https://www.emergenresearch.com/industry-report/femtech-market

For the purpose of this report, Emergen Research has segmented into the Global Femtech Market on the basis of type, end-use, application, and region:

Type Outlook (Revenue: USD Billion; 2017-2027)

End Use Outlook (Revenue: USD Billion; 2017-2027)

Application Outlook (Revenue: USD Billion; 2017-2027)

Regional Outlook (Revenue, USD Billion; 2017-2027)

Find more research reports on healthcare and pharmaceuticals industry, by Emergen Research:

Regenerative Medicine MarketRegenerative Medicine Market By Product (Tools, Therapeutics), By Therapeutic Category (Musculoskeletal, Dermatology, Immunology & Inflammation, Cardiovascular), and By Applications (Wound Care, Musculoskeletal Disorders, Ocular Disorders), Forecasts to 2027

Next-Generation Sequencing MarketNext-Generation Sequencing Market by Technology (Whole Exome, Whole Genome, Others), By Workflow (Sequencing, Pre-Sequencing, Others), By Application (Consumer Genomics, HLA Typing, Others) and By End-Use (Academic, Clinical, Others), Forecasts to 2027

RFID in Healthcare MarketBy Product (Tags, Systems & Software) and By Application (Asset Tracking, Patient Tracking, Pharmaceutical Tracking, Blood Tracking, Others), Forecasts to 2027

Non-Invasive Prenatal Testing MarketBy Method, By End-Use, By Application, By Region, Forecasts to 2017-2027

Viral Vector and Plasmid Manufacturing MarketBy Vector Type (Retrovirus, Adenovirus, Others), By Workflow (Upstream, Downstream), By Disease (Cancer, Genetic Disorders, Others), By Application (Gene Therapy, Retailers) and By End-User, Forecasts to 2027

Interoperability Solutions in Healthcare MarketBy Level (Foundational, Structural, Semantic), By Product Type (Services, Solutions), and By Application (Diagnostics, Treatments, Others), Forecasts to 2027

About Emergen Research

At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

With market-leading insights and an in-depth understanding of leading and niche technologies, our solutions address the most pertinent questions for your business needs. A major technological shift has been witnessed towards creating a 'Circular Economy,' fuelled by factors, such as the increased adoption of bio-based materials, along with other methods for achieving carbon neutrality. We are conversant in technologies, viz., Artificial Intelligence (AI), Augmented Reality (AR), Virtual Reality (VR), Robotic Process Automation (RPA), Smart Manufacturing, Internet of Things (IoT), Big Data Analytics, Machine learning, Nanotechnology, Edge Computing, Blockchain Technology, Cloud Computing, Vehicle Electrification, Advanced Maintenance Analytics, and Predictive Maintenance, among other prevalent and emergent technologies.

Contact Us:Eric LeeCorporate Sales SpecialistEmergen Research | Web: https://www.emergenresearch.comE-mail: [emailprotected]

Read full Press Release at :https://www.emergenresearch.com/press-release/global-femtech-market

SOURCE Emergen Research

Original post:
Femtech Market to Reach USD 60.01 Billion By 2027 | CAGR of 15.6%: Emergen Research - PRNewswire

September 14, 2020 NIH contracts to explore radiation countermeasures, Alzheimers medication, and convalescent plasma, Mission Bio gets $70M for single cell multi-omics technology, and more.

$300M: Series D for New Materials

Science and material innovation company Zymergen (Emeryville, Calif.) has announced $300M in new investment to accelerate its delivery of revolutionary, high performance materials. The investment includes initial Series D funding led by Baillie Gifford, joined by Baron Capital Group and one of the worlds largest sovereign wealth funds, as well as additional growth financing from Perceptive Advisors. A number of current investors are also returning, and Zymergen expects to raise additional capital in Q4 as part of a Series D round. Zymergen develops and launches better performing products more sustainably and for a fraction of the cost and time that it typically takes using incumbent techniques. A unique combination of biology, chemistry, machine learning and lab automation underpins Zymergens powerful proprietary platform, driving the companys ability to discover, design and commercialize never-before-seen materials.

$270M: Series C for Multiomics Blood Testing for Cancer

Freenome (South San Francisco, Calif.) announced an oversubscribed $270M Series C financing to accelerate the PREEMPT CRC clinical trial for Freenomes blood test for colorectal cancer screening and precancerous lesion detection, advance a pipeline of blood tests for both the early detection and early intervention of additional cancers, and continue building the companys proprietary multiomics platform. PREEMPT CRC is an FDA registrational study launched in May 2020 to support approval by the U.S. Food and Drug Administration (FDA) for the first front-line blood test to help the 45 million people who are currently not up-to-date on colorectal cancer screening guidelines in the U.S. The Series C financing was led by new investor Bain Capital Life Sciences and existing investor Perceptive Advisors. They were joined by a group of other new investors, including Fidelity Management & Research Company, LLC, Janus Henderson Investors, Farallon Capital Management, Rock Springs Capital, Cormorant Asset Management, EcoR1 Capital, LLC, Catalio Capital Management, and the Colorectal Cancer Alliance.

$100M: Radiation Countermeasures

SRI International (Menlo Park, Calif.) has been awarded a seven-year contract of up to $100 million from the National Institutes of Healths (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to support the research and development of radiation/nuclear medical countermeasures (MCMs). Under the contract, SRI Biosciences, a division of SRI International, will provide facilities, expertise, and capabilities to advance the development of MCMs for the mitigation or treatment of acute radiation syndromes as well as the treatment of delayed effects from acute radiation exposure (ARS/DEARE) and internal radionuclide contamination. SRI researchers will also support NIAIDs ongoing biodosimetry efforts.

$74M: Five-Year NIH Grant To Test Alzheimers Meds

Alzheon (Framingham, Mass.) has announced today that the U.S. National Institute on Aging (NIA) has awarded the company a grant expected to total $47 million over 5 years to support a Phase 3 clinical study with ALZ-801, an oral agent that blocks the formation of neurotoxic soluble amyloid oligomers. The study will enroll Early AD patients, who have two copies of the apolipoprotein e4 allele (APOE4/4). AD patients with this genetic profile have been shown to have a higher risk of rapid disease progression and to be responsive to agents targeting pathogenic amyloid oligomers.

$70M: Series C for Single Cell Multi-Omics Technology

Mission Bio (South San Francisco, Calif.) announced $70 million in its Series C financing led by Novo Growth, the growth equity arm of Novo Holdings. Soleus Capital also joins the round, along with earlier investors Mayfield, Cota, and Agilent, bringing the companys total funding to more than $120 million. The funds will be used to scale its single-cell multi-omics technology, the Tapestri Platform, to expand the companys reach in more effective clinical trials for novel cancer treatments, as well as characterization for cell and gene therapy.

$50M: Decentralized Research

THREAD (Durhan, NC) received additional capital commitment of up to $50 million from strategic health care investors, Water Street Healthcare Partners and JLL Partners. The companys latest capital infusion builds on a year of significant growth and investments in its platform and services to advance decentralized research approaches for large-scale, Phase Ib - IV global clinical trials. To date, THREAD has supported more than 100 decentralized studies. The company will continue to invest in expanding and enhancing its innovative platform and supporting services.

$40M: Decentralized Clinical Trials

Science 37 (Los Angeles) has closed an oversubscribed $40 million funding round. Existing investors Lux Capital, Redmile Group, and PPD, Inc. led the round, and are joined by existing investors Novartis, Amgen, Sanofi Ventures, GV, and Glynn Capital. Notable new investors include LifeSci Ventures and Mubadala Ventures. Science 37 will use the new capital to support its rapid growth, expand its technology platform, and accelerate its global expansion effortsfurther strengthening its ability to help sponsors execute decentralized trials and enable patients to participate in trials from anywhere, without the burden of traveling to a traditional clinical site.

$34M: NIH Grant for Nationwide Study of Convalescent Plasma

Vanderbilt University Medical Center (Nashville, Tenn.) has been awarded a one-year, $34-million grant by the National Center for Advancing Translational Sciences, part of the National Institutes of Health, to conduct a nationwide study of "convalescent plasma" as a treatment for COVID-19. The randomized, controlled trial will test whether infusions of plasma, the liquid part of blood collected from COVID-19 survivors, can help other hospitalized patients with COVID-19. The study will recruit 1,000 participants in approximately 51 sites across the country. The goal is to complete enrollment by October 31, and report results by November.

$25.5M: Series B for Healthcare Interoperability

Bridge Connector (Nashville, Tenn.), an interoperability company changing the way health care communicates, today announced it has raised $25.5 million in Series B financing. The latest round, led by Axioma Ventures, was joined by all existing investors, including veteran investor Jeff Vinick, and brings Bridge Connectors total funding to over $45 million. After achieving over 1000% year-over-year growth in 2019, the investment will further support the companys increasing market share in health care interoperability and growth of Destinations, a new integration-platform-as-a-service (iPaaS) that connects health data systems using use-case-based interoperability blueprints to speed integrations with major vendors. Bridge Connector provides a suite of vendor-agnostic integration solutions and a full-service delivery model, helping health care vendors, providers, and payers more easily share data between disparate systems, such as electronic health records (EHRs) or patient engagement solutions.

$12M: Cloud Clinical Data Platform

Castor (Hoboken, New Jersey) has announced a $12 million funding round led by Two Sigma Ventures with participation from Hambrecht Ducera Growth Ventures and existing investor INKEF Capital. Castors clinical data platform that simplifies the clinical trial process, from recruitment to analysis, for researchers globally. Its used by more than 50,000 users across academia and commercial research, powering more than 4,000 studies with more than 2,000,000 enrolled patients across 90 countries. 192 medical device, biotech, and pharmaceutical companies and contract research organizations (CROs) are using Castors platform. Castor made its platform freely available for all non-profit COVID-19 research starting in February.

$11.8M: Series A for Digital Sedation

Oncomfort (Brussells), the Belgian inventor of and leader in Digital Sedationa method for relieving patients' pain and anxiety without medicationhas completed a 10 million Series A funding round co-led by two prominent institutional investors: Debiopharm and Crdit Mutuel Innovation. Oncomfort plans to use this investment to develop its innovative digital therapy solutions and accelerate its international expansion in Europe and the US. Founded in 2017, Oncomfort invented Digital Sedation, a completely new method for relieving patients' pain and anxiety through treatment with clinically proven sessions of therapeutic Virtual Reality. Since the launch of the Sedakit for Digital Sedation in Benelux and France in June 2019, over 30,000 patients have been treated and have had their pain and anxiety relieved before, during, and after interventions in many clinical fields such as anesthesia, oncology, interventional radiology and cardiology, as well as pediatrics.

$9.94M: Five Year NIH Grant for Rare Genetic Diseases

Baylor College of Medicine (Houston, Tex.) has received a five-year, $9.94 million grant from the National Institutes of Health for the new Center for Precision Medicine Models to facilitate the study of rare genetic diseases. The center will use precision animal models of a patients or group of patients specific genetic variation and study why the change causes disease and how the disease can be treated. The center will take nominations for genetic variants to model from patients, patient groups, clinicians, researchers, and NIH-funded consortiums like the Undiagnosed Diseases Network and the Centers for Mendelian Genomics. An accepted disease-causing genetic variant must previously be identified in order to be considered for modeling. After a case is submitted, the centers clinical and bioinformatics teams will independently assess the genetic variant for likelihood of causing disease. Next, the modeling team will decide if a precision model organism can be produced for that particular genetic change and whether appropriate resources are available within the center to study the disease. A final decision about whether to select the case will be made based on likely clinical benefit to the patient.

$3M: Series of Grants from Society to Improve Diagnosis in Medicine

The Society to Improve Diagnosis in Medicine (SIDM) is issuing the first of three grant rounds, totaling $3 million, as part of the organizations DxQI Seed Grant Program. The initial awards are up to $50,000 for 17 organizations testing interventions to improve the quality, accuracy, and timeliness of diagnoses. The 17 grantees awarded in this round are: Advocate Aurora Health; Atrium Health; The Atrium Health Levine Childrens Hospital; Beth Israel Deaconess Medical Center; Brigham Health/Brigham and Womens Hospital; The Johns Hopkins University School of Medicine; Kaiser Permanente East Bay; Maine Medical Center; McMaster University; MedStar Health; Northwell Health; Northwestern Memorial HealthCare; Tufts Medical Center and Floating Hospital for Children; The University of Michigan and Hurley Medical Center; The University of Texas Health Science Center at San Antonio & University Health System; The University of Pittsburgh School of Medicine, and The Veterans Education and Research Association of Michigan and VA Ann Arbor Healthcare System.

$1.5M: Regulatory Information Management Solutions

Rimsys (Pittsburgh, Penn.) closed a $1.5 million investment round, led by Allos Ventures. The financing round will support Rimsys penetration of the MedTech Regulatory Information Management market through planned expansions of its product offering, sales, and marketing execution. Rimsys solution seamlessly integrates with MedTech manufacturers existing quality management systems, product lifecycle management systems, and sales and distribution software systems. Rimsys robust digital platform, with its intuitive user interface and global intelligence, enables its customers to meet market entrance requirements and grow internationally. John McIlwraith, managing director at Allos Ventures will join Rimsys board of directors.

$1.3M: AI for Drug Repurposing for COVID-19

Relation Therapeutics (London), a drug development company driven by data science and machine learning (ML), has announced Project RE, which will apply Relation Therapeutics and its partners technology to the identification of repurposed drug combinations as potential therapeutic candidates for COVID-19. Funding for Project RE is provided by a $1.3 million grant from the Bill & Melinda Gates Foundation to Relation Therapeutics. Project RE will focus on finding therapies to tackle viral entry and replication and is co-led between Mila (Quebec AI Institute) and Relation Therapeutics, with the overall scientific direction by Mila founder Professor Yoshua Bengio. The project will also create a platform to develop therapies that appropriately modulate the immune response through distinct stages of infection with oversight from Relations Chief Medical Officer, Dr. David Roblin.

$356,000: AI for Microbiome-Disease Link

BioLizard (Ghent, Belgium) received a 300,000 research grant from Flanders Innovation & Entrepreneurship (VLAIO) to leverage its world-leading expertise in bioinformatics, AI and machine learning, to establish the causal link between the human microbiome and disease. Collecting data from the broadest set of microbes, patient background and interactions, BioLizard is building a framework using state-of-the-art bioinformatics and AI tools to evaluate causal links in the human microbiome, purely from data. This will allow evaluation of whether microbe A causes disease B or if theyre only distantly related, thereby requiring a refining of focus.

$100,000: COVID-19 Fast Grant for Enzymes Critical to SARS-CoV-2 Replication

Dr. Christopher Basler, professor and director of the Center for Microbial Pathogenesis in the Institute for Biomedical Sciences at Georgia State University, has received a $100,000 COVID-19 Fast Grant to study enzymes that are critical for the replication of SARS-CoV-2, the virus that causes COVID-19. Basler is exploring several small molecule inhibitors that would block formation of membranes needed for SARS-CoV-2 infection. These include enzymes such as VPS34, long chain fatty acyl-coA synthetase and fatty acid synthase. Drugs that affect cell membranes and lipids are being pursued as treatments for other medical conditions, including cancer, diabetes and obesity. Early data from the Basler lab suggest such drugs might be effective to slow SARS-CoV-2.

See the article here:
Follow the Money: Alzheimer's Meds, Single Cell Multi-Omics Technology - Bio-IT World

While there is no cure for blindness and macular degeneration, scientists have accelerated the process to find a cure by visualizing the inner workings of the eye and its diseases at the cellular level.

In an effort led by UW Medicine, researchers successfully modified the standard process of optical coherence tomography (OCT) to detect minute changes in response to light in individual photoreceptors in the living eye.

The results were published Sept. 9 in Science Advances.

We have now accelerated the life cycle of vision restoration, said lead author Vimal Prabhu Pandiyan, a ophthalmology researcherat the University of Washington School of Medicine.

The study was fundedin partby the National Eye Institutes Audacious Goals Initiative, which embraces bold ideas in helping people to see better.

The OCT modifications outlined in the study will help researchers who want to test therapiessuch as stem cells or gene therapy to treat retinal disease. They now have the tools to zoom in on the retina to evaluate whether the therapy is working.

Corresponding author Ramkumar Sabesan, a UW assistant research professor of ophthalmology, said the only wayto objectively measure the eye currently is to look at a wide retinal area. Sabesan said researchers currently can attach electrodes on the cornea but it captures a large area with around 1 million cells. Now they are talking about nanometers, or one billionth of a meter a small fraction of the size of a cell, providing orders of magnitude improvement.

Since photoreceptors are the primary cells affected in retinal generation and the target cells of many treatments, noninvasive visualization of their physiology at high resolution is invaluable, the researchers wrote.

Cone photoreceptors are the building blocks of sight, capturinglight and funneling information to the other retinal neurons. They are a key ingredient in how we process images and patterns of light falling on the retina.

Optical coherence tomography has been around since the 1990s. In this study, researchers used OCT with adaptive optics, line-scanning and phase-resolved acquisition to deliver the concept of Thomas Youngs interference to the human eye. With the ability to zoom in on the retina at high speeds, they found that cone photoreceptors deform at the scale of nanometers when they first capture light and begin the process of seeing.

As Sabesan explained: You can imagine a picture that looks visually and structurally normal. But when we interrogate the inner working of the retina at a cellular scale, we may detect a dysfunction sooner than what other modalities can do. A doctor then can prescribe medication to intervene early or follow the time-course of its repair via gene therapy or stem cell therapy in the future.

We will now have a way to see if these therapies are acting in the way they should, Sabesan said.

The study also involved researchers at Stanford University, University of California,Berkeley, and University of California, Riverside.

The study was funded by NIH grants U01EY025501, EY027941, EY029710, EY025501, and P30EY001730; Research to Prevent Blindness Career Development Award; Foundation Fighting Blindness; Murdock Charitable Trust; Burroughs Welcome Fund Careers at the Scientific Interfaces; and Unrestricted grant from the Research to Prevent Blindness.

Go here to read the rest:
Seeing the eye like never before | Newsroom - UW Medicine Newsroom

DUBLIN, Sept. 14, 2020 /PRNewswire/ -- The "17th Annual Report and Survey on Biopharmaceutical Manufacturing Capacity and Production" report has been added to ResearchAndMarkets.com's offering.

The 2020 17th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production is the most recent study of biotherapeutic developers and contract manufacturing organizations' current and projected future capacity and production.

This report's data-rich analysis will help improve your decision-making in biomanufacturing operations, with in-depth analysis of capacity, production trends, benchmarks, and much more.

In-depth analysis and summary of the key survey findings, trends and implications for industry-wide biomanufacturing capacity and biotherapeutic production. Comparison of production by biotherapeutic developers and contract manufacturing organizations. Current and future potential industry bottlenecks.

Key Topics Covered:

CHAPTER 1: INTRODUCTION AND DISCUSSION1-1 Introduction: The Pharmaceutical and Biopharmaceutical Industries1-2 Current Status and Market Trends1-3 Market Potential1-4 Biopharmaceuticals and Biosimilars in the Pipeline1-5 Global Biopharmaceutical and Recombinant Protein/MAb Markets1-6 Biopharmaceutical Markets by Product Class1-7 Animal Derived Products and Biopharmaceuticals1-8 Future Trends in the Biopharmaceutical Industry1-9 Future Biopharmaceutical Market Trends

CHAPTER 2: FUTURE OF BIOPROCESSING: EXPERTS' PERSPECTIVE2-1 Cell and Gene Therapy - Future of Bioprocessing2-2 Continuous Processing - Present and Future Challenges2-3 China and Asia's position in Global Bioproduction2-4 Intersection of Biopharma and Small Pharma: Small Molecule Manufacturing Lessons for a New Industry2-5 Upstream and Downstream Biologics Manufacturing: Mapping the Future Challenges and Trends2-6 Suppliers' Contributions to Bioprocessing Advances2-7 Contract Manufacturing's Contributions to Bioprocessing Advances2-8 Worldwide Biopharmaceutical Manufacturing Capacity Analysis: Growth Continues Across the Board2-9 China's Advances in Global Biopharma and Bioprocessing: A 10-year Projection on Need for Quality Improvements

CHAPTER 3: EMERGING ISSUES IN BIOPHARMACEUTICAL MANUFACTURING3-1 Industry Trends in 20183-2 Budget Issues in 20183-3 Operational Changes3-4 New Bioprocessing Products Development Opportunities in 20183-5 Factors in Biomanufacturing Creating Improvements3-6 Cost-Cutting Actions & Development Timelines (2016 data)3-7 Average Cost per Gram Recombinant Protein3-8 Assay Development3-9 Perfusion Operations and Continuous Bioprocessing Operations Issues3-10 Perfusion Operations and Continuous Bioprocessing Trends3-11 Discussion3-12 Cell and Gene Therapy Platforms3-13 Selecting Bioreactors in New Facilities (2017 data)3-14 Discussion: Industry Trends and Issues

CHAPTER 4: CAPACITY UTILIZATION4-1 Capacity Utilization Trends4-2 Capacity Utilization: CMOs vs. Biotherapeutic Developers4-3 Capacity Utilization: U.S. vs. Western European Manufacturers4-4 Respondents' Current Total Production Capacity4-5 Discussion: Capacity Trends4-6 Range of Titers with mAb Production4-7 Discussion: Capacity and Industry Trends

CHAPTER 5: CURRENT AND FUTURE CAPACITY CONSTRAINTS5-1 Current Capacity Constraints5-2 Expected Capacity Constraints 210 Respondents' Expectations of Capacity Constraints by 20235-3 Factors Impacting Future Production Capacity5-4 Key Areas to Address to Avoid Future Capacity Constraints5-5 Discussion

CHAPTER 6: FUTURE CAPACITY EXPANSIONS6-1 Planned Future Capacity Expansions

CHAPTER 7: OUTSOURCING TRENDS IN BIOPHARMACEUTICAL MANUFACTURING7-1 Current Outsourcing by Production System7-2 Future Outsourcing7-3 Outsourced Activities in Biopharmaceutical Manufacturing7-4 Critical Outsourcing Issues7-5 CMOs' Problems with Their Clients7-6 Country Selections for International Outsourcing (Off-shoring) of Biomanufacturing7-7 Offshoring Trends7-8 5-Year Projection for Percentages of Biomanufacturing International Outsourcing/Off-shoring

CHAPTER 8: DISPOSABLES AND SINGLE-USE SYSTEMS IN BIOPHARMACEUTICAL MANUFACTURING8-1 Use of Disposables and Single-Use Systems8-2 Leachables and Extractables8-3 Reasons for Increasing Use of Disposables & Single-Use Systems 3268-4 Factors That May Restrict Use of Disposables8-5 Suppliers' Expectations for Standards Setting Bodies8-6 Need for Single-use Sensors, and Bioreactor Attributes8-7 Satisfaction with Single-use Device Vendors8-8 Single Use Operations and Trends8-9 Discussion of Single-use Bioprocessing

CHAPTER 9: DOWNSTREAM PURIFICATION9-1 Impact of Downstream Processing on Capacity9-2 Specic Purication Step Constraints9-3 Downstream Purication Issues9-4 mAb Purication Capacity Estimates9-5 New Downstream Processing Technologies9-6 Improvements to Downstream Operations9-7 Discussion

CHAPTER 10: QUALITY ISSUES, BATCH FAILURES, AND PAT IN BIOPHARMACEUTICAL MANUFACTURING10-1 Quality Initiative Implementation10-2 Hurdles to Implementing Process Analytical Technology10-3 Batch Failure Frequency in Biopharmaceutical Manufacturing10-4 Primary Cause of Batch Failures, Percentages of Failures10-5 Quality Problems in BioManufacturing Attributed to Vendors10-6 Discussion

CHAPTER 11: HIRING, EMPLOYMENT GROWTH, AND TRAINING IN BIOPHARMACEUTICAL MANUFACTURING11-1 Hiring Trends11-2 Hiring in 2023: 5-year Trends11-3 Hiring Challenges Today11-4 Training in Biopharmaceutical Manufacturing11-5 Intersection of Biopharma and Small Pharma11-6 Discussion

CHAPTER 12: New Methods: Continuous and Process Intensification, Cell and Gen12-1 PerfusionAreas of Involvement12-2 Trends in Fill-Finish and Related Bioprocessing Capacity12-3 Current Fill-Finish Trends12-4 Discussion

CHAPTER 13: SUPPLIERS TO BIOPHARMACEUTICAL MANUFACTURING AND LIFE SCIENCES13-1 Demographics13-2 Growth Rate of Sales by Suppliers13-4 Budget Issues and Problems Faced by Industry Suppliers13-5 Cost Cutting Actions by Vendors13-6 Problems Clients Have with Their Vendors13-7 Vendor Expansion Plans13-8 New Technology Areas in Development by Vendors13-9 Sales Staff Training 502 Days of Training Provided13-10 Biopharma Vendors' Financial Outlook for 201813-11 Discussion of Biopharma Suppliers

For more information about this report visit https://www.researchandmarkets.com/r/3bdm10

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Go here to see the original:
Global Bio-pharmaceutical Manufacturing Capacity and Production Report 2020: Comparison of Production by Biotherapeutic Developers and Contract...

Silence Therapeutics Appoints Mark Rothera as President and Chief Executive Officer

Experienced biotech executive to lead the next phase of growth

14 September 2020

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (Silence or the Company), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces the appointment of Mark Rothera as President and Chief Executive Officer (CEO) and Board member, effective immediately. Iain Ross, who has been Executive Chairman since December 2019, has today assumed his previous position of Non-Executive Chairman.

Mr. Rothera brings more than 30 years of experience in the biopharmaceutical industry, with a strong record of commercial and operational leadership, including driving the successful build of multiple biotech companies, predominantly in the field of rare or specialty diseases. Prior to joining Silence, Mr. Rothera served as CEO of Orchard Therapeutics (Orchard), where he oversaw its transformation from a small U.K.-based, privately held company with two clinical-stage programmes into a leading gene therapy company with seven clinical-stage programmes and fully integrated capabilities. Under his leadership, Orchard completed an initial public offering of American Depositary Shares on the Nasdaq Global Market and during his tenure that company secured more than $600 million in financing and grew from a market capitalization of $250 million to more than $1.7 billion at its peak.

Prior to Orchard, Mr. Rothera served as Chief Commercial Officer of PTC Therapeutics (PTC), where he helped transition that company from a privately held R&D biotechnology company to a publicly traded, commercial-stage company with a global footprint, including the successful launch of two rare disease therapies. He also previously served as Global President of Aegerion Pharmaceuticals Inc. and Vice President and General Manager of commercial operations at Shire Human Genetic Therapies for Europe, Middle East and Africa. Mr. Rothera received an M.A. in Natural Sciences from Cambridge University and an M.B.A. from the European Institute for Business Administration (INSEAD).

Based out of Silences New York City office, Mr. Rothera will lead the continued global expansion of the Company. His appointment follows the completion of Silences Nasdaq listing on 8 September 2020 and aligns with the strategy of increasing the Companys presence in the United States.

Iain Ross, Chairman of Silence Therapeutics plc, said: "On behalf of the Silence Board and the entire Silence team, I welcome Mark to the Company. Following a thorough search, Marks appointment reflects his proven leadership skills and strong track record in growing successful biotechnology companies and building shareholder value. I believe he will now provide the leadership necessary to grow Silence into a leading international biotechnology company built upon our innovative siRNA technology platform, proprietary product pipeline and validating industry partnerships.

On a personal note, and on behalf of the Board, I would like to thank the management team and staff at Silence for their support, hard work and tremendous resilience during the current COVID-19 pandemic and over the past nine months whilst I have been Executive Chairman. The Company has made great strides during this period, and is now in a strong position, both operationally and financially, and ready for Mark to take the helm.

Mark Rothera, President and CEO of Silence Therapeutics plc, added: It is an honour to take the role of leading Silence at this time in the Companys history. I believe the Company is poised to capitalise on its important siRNA technology platform, pipeline and research capabilities built over 18 years, and position itself as a leader in the RNAi field. The Company has made great strides under Iains leadership and I look forward to working with the Board, the management team and Silence employees to build upon this momentum.

Director disclosures

The following information is being disclosed pursuantto Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Mark Rothera

Full name and age: Mark Andrew Rothera (aged 58)

Current Directorships or Partnerships:Genpharm

Previous Directorships or Partnerships in the last 5 years:Orchard Therapeutics plcPTC Therapeutics International LimitedAlliance for Regenerative Medicine

No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

Enquiries:

About Silence TherapeuticsSilence Therapeutics is developing a new generation of medicines by harnessing the bodys natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silences proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silences wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing SLN500 in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases. Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

The person who arranged for the release of this announcement on behalf of the Company was Rob Quinn, Chief Financial Officer.

Forward-Looking StatementsCertain statements made in this announcement are forward-looking statements, including with respect to the Companys clinical and commercial prospects. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

See more here:
Silence Therapeutics Appoints Mark Rothera as President and Chief Executive Officer - GlobeNewswire

Report Ocean announces the release of Cell and Gene Therapy Market research report. As per Report Ocean, the market is expected to grow at a healthy pace in the coming years. Leading market vendors are focusing on the development of their mergers & acquisitions with the main aim of providing a broad geographical presence to multiple industries. Most players are anticipated to adopt three key business strategies to cement their position in the market, i.e. expanding product portfolio, facilitating product differentiation, and participating in mergers and acquisitions.

Industry challenges together with the latest developments in the technological developments of the Cell and Gene Therapy Market have been elaborated on in the market intelligence report. It also provides a detailed picture of the trends of the changing industry structure and the challenges that are faced by various industry participants. The report elaborates on the major challenges that the participants of the said market could possibly across the globe.

Request Free Sample Report athttps://reportocean.com/industry-verticals/sample-request?report_id=mai52690

The outbreak of Covid-19 has brought in uncertainties and disruptions for the present and future of several businesses across the globe. The pandemic has claimed both lives and livelihoods, there leaving little or no hope till a vaccine for Covid-19 arrives. However, analysts at Report Ocean make a careful and meticulous assessment of the present situation and disruptions caused by the virus in the supply chain to draw estimates, projections and avenues of growth for the Cell and Gene Therapy Market.

The objectives of this study are to define, segment, and project the size of the Cell and Gene Therapy Market based on company, product type, end user and key regions.

Competitive Landscape:

The report also includes several valuable information on the Cell and Gene Therapy Market, derived from various industrial sources. The report studies the competitive environment of the Cell and Gene Therapy Market report is based on company profiles and their efforts on increasing product value and production.

Key parameters which define the competitive landscape of the Cell and Gene Therapy Market:

Revenue and Market Share by Player

Production and Share by Player

Average Price by Player

Base Distribution, Sales Area and Product Type by Player

Concentration Rate

Manufacturing Base

Mergers & Acquisitions, Expansion

Market Segmentation:

The major factors are also being considered while studying the various market segmentation. Some of the key factors are study of demand and supply of Cell and Gene Therapy Market, common interests and market share of the global Cell and Gene Therapy Market market across various geographies.

Geographical Analysis

Geographically, this report is segmented into several key regions, with sales, revenue, market share, and Cell and Gene Therapy Market growth rate in these regions, from 2015 to 2026, covering;

North America (U.S. and Canada)

Europe (UK, Germany, France, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, India, Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam)

South America (Brazil, Argentina, Mexico, and Rest of South America)

The Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria)

Some of the Major Highlights of TOC covers:

Cell and Gene Therapy Market Production, Revenue (Value), Price Trend by Type

Production and Market Share by Type

Revenue and Market Share by Type

Price by Type

Cell and Gene Therapy Market Analysis by Application

Consumption and Market Share by Application

Cell and Gene Therapy Market Production, Consumption, Export, Import by Region

Production, Consumption, Export, Import by Region

Production, Consumption, Export, Import by Country

Production, Revenue, Price and Gross Margin

Cell and Gene Therapy Market Manufacturing Analysis

Key Raw Materials Analysis

Market Concentration Rate of Raw Materials

Manufacturing Cost Analysis

Labor Cost Analysis

Manufacturing Cost Structure Analysis

Manufacturing Process Analysis of XYZ

Industrial Chain, Sourcing Strategy and Downstream Buyers

Cell and Gene Therapy Market Industrial Chain Analysis

Raw Materials Sources of Cell and Gene Therapy Market Major Players in 2019

Downstream Buyers

Market Dynamics

Market Drivers

Restraints

Opportunities

Increased Demand in Emerging Markets

Challenges

Porters Five Forces Analysis

Cell and Gene Therapy Market Forecast

Production, Revenue Forecast

Production, Consumption, Export and Import Forecast by Region

Production, Revenue and Price Forecast by Type

Consumption Forecast by Application

Note In order to provide more accurate market forecast, Cell and Gene Therapy Market report will be updated before delivery by considering the impact of COVID-19.

Inquire or Share Your Questions If Any before Purchasing This Report:https://reportocean.com/industry-verticals/sample-request?report_id=mai52690

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, and Asia.

Contact Us: +1 888 212 3539 (US) +91-9997112116 (Outside US)Contact Person: Matthew SEmail:[emailprotected]

Read more from the original source:
COVID-19 Impact and Recovery Analysis - Cell and Gene Therapy Market 2020-2026 - The Market Chronicles

Global Exosome Therapeutic Market By Type (Natural Exosomes, Hybrid Exosomes), Source (Dendritic Cells, Mesenchymal Stem Cells, Blood, Milk, Body Fluids, Saliva, Urine Others), Therapy (Immunotherapy, Gene Therapy, Chemotherapy), Transporting Capacity (Bio Macromolecules, Small Molecules), Application (Oncology, Neurology, Metabolic Disorders, Cardiac Disorders, Blood Disorders, Inflammatory Disorders, Gynecology Disorders, Organ Transplantation, Others), Route of administration (Oral, Parenteral), End User (Hospitals, Diagnostic Centers, Research & Academic Institutes), Geography (North America, Europe, Asia-Pacific and Latin America)

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

To Remain Ahead Of Your Competitors, Request for a FREE Sample Here (with covid 19 Impact Analysis) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&DW

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

Make an Enquiry before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&DW

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process.

The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

The major players covered in the report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Read More@ https://www.databridgemarketresearch.com/reports/global-exosome-therapeutic-market?DW

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email @ Corporatesales@databridgemarketresearch.com

Read the original here:
Exosome Therapeutic Market (Covid 19 Impact Analysis) Data Highlighting Major Vendors, Promising Regions, Anticipated Growth Forecast To 2027 - Good...

Population

During the first stage (first two rounds of interviews) five focus groups and 36 individual interviews were performed. In the second stage (round three), five focus groups and 21 individual interviews were performed.

A total of 136 individuals participated in the study: 85 (62.5%) women and 51 (37.5%) men; median age was 26 (range 1944) years for women and 29 (range, 1959) years for men; 77 (56.6%) participants had completed secondary school (Table1). Approximately 5% refused to participate in the study mostly citing personal reasons and lack of time.

The result sections are organized to highlight issues in contraception, ZIKV infection and PAC services, respectively.

Most participants knew at least one contraceptive method. The most frequently mentioned were pills, injections and implants, while less frequently mentioned methods were intrauterine devices (IUD), male condoms and surgical sterilisation. Both female and male participants knew about female condoms but lacked detailed information about them. Both men and women said that although they knew they could choose different contraceptive methods, they would like to receive more detailed information on each individual method, specifically regarding their adverse effects and efficacy.

They dont provide advice regarding family planning and they only ask What kind of family planning do you want? without informing the patient about the side effects of the different methods, for example the risks that an IUD can bring in the future, or the risks of the injection, so I end up choosing the method that a friend recommended. (Focus Group, women, Hospital).

Participants generally had a positive attitude towards the use of contraceptive methods. Women and their partners said they did not feel stigmatized for seeking information on methods at the health facilities. Few men acknowledged they did not allow their partners to use contraceptive methods, while others considered contraceptive use should be a shared decision. Despite the knowledge about contraceptive methods and the positive attitude, many participants specified that their children had not been planned. In fact, many women said that they had sought contraceptive methods only after giving birth.

Many participants shared doubts about the effectiveness and the adverse effects associated with contraceptive methods and had concerns on the lack of comfort when using them. Most participants believed that the effectiveness of each contraception method varied with each person. In fact, women thought that although physicians had information on the methods, they may not know how individual womens bodies would react to each method. Many participants provided anecdotes involving the experience of friends or family that supported their perception that any method, even surgical sterilisation, could fail.

This guy had sex with a lady, and she got pregnant, and he said it was not his baby . And then there was a fight at home. When he came to the hospital he got examined and he really was fertile even though he had been operated! Could you just imagine if he had killed that woman! (Focus Group, Women, Clinic).

Women most commonly accepted and used hormonal contraception; indeed, many preferred the three-month injection because it was freely distributed at the public hospital and was easily accessed. Participants main concerns regarding hormonal methods were their efficacy and their association with cancer, infertility, weight gain and skin blotches.

I am scared of implanon [implant], Im honest. No doctor will tell you the truth, they tell you the implanon will cover this or that, but they wont tell you that in the future it will give you cancer. (Focus Group, Women, Clinic).

Pills though had a burdensome daily regimen, were considered a very effective method. Participants had information on morning-after pills but explained that the use of this method was frequently associated with rape. For men, the most popular method were male condoms; however, they would use it for the prevention of sexual transmitted diseases (STI) rather than for contraception. Of note, only a few participants included Zika in the group of diseases that could be prevented through condom. Some male participants were aware of surgical sterilisation (vasectomy), although only very few men were considering having it.

Participants observed that opening hours at health centres were limited and that the distance between their homes and the health facilities was a significant access barrier. Therefore, participants often arrived at the hospital at 4am to secure an appointment. Most of the participants said that the admission process was disorganized and difficult and that waiting times were very long and thought the probable cause of delays was insufficient numbers of staff and lack of administrative organization.

Look, I came here on Sunday, at 9 am and they told me I had to come back at 1pm. I came back at 1pm and they told me they were not open because they were going to disinfect the place. So, I came back on Monday and told me to stay on a line of people, I tried to explain to the girl, so they told me to return in the afternoon. (Interview, Woman, Clinic).

Regarding infrastructure, some participants complained that the toilets were not clean; however, at the last round of survey, a few participants acknowledged there had been some improvements in cleanliness and infrastructure.

Participants considered that counselling services on reproductive health, especially on contraception were inconsistent and insufficient. Those who wanted to use contraception, received information provided at compulsory meetings only. Several participants suggested that health professionals should proactively approach people and give them more information on reproductive health and that counselling service should be extended to all even during the afternoons and evenings.

The service here (public health centre) is not the same as in a private clinic where you have to pay because here there are so many people. The doctors have to see so many people that they cannot have a special relationship with you (Focus Group, Women, Clinic).

Some women felt uncomfortable during the consultations due to lack of privacy. They would prefer female providers.

I dont know why, but with women we have more confidence, though some men are more sensitive sometimes, but for intimacy issues it is better to have a woman [as health personnel]. (Focus Group, Women, Hospital).

Often, single women sought counselling service and information in clinics outside their communities to avoid the embarrassment of being recognised by neighbours or healthcare staff. Moreover, it was reported that, sometimes, confidentiality was ignored by health staff, and this contributed to users mistrust in the services.

You know what Id change? Id make this office private for women who come here for the (DMPA) shot, because you have to pull down your trousers, and you really feel embarrassed, sometimes in presence of three, four, five other people there (Focus Group, Women, Clinic).

Participants stated that they could receive some contraception methods free of charge, including three-month injection, condoms and IUD. However, participants perceived that the condoms freely distributed at health facilities were small and of bad quality; therefore, when needed, they preferred buying at the pharmacies. Those condoms were considered to be inexpensive, of better quality and accessible in nearby vicinity. No improvement in services were perceived by the participants throughout the interview rounds.

Participants were aware that Zika was mainly transmitted by mosquitoes. Participants mentioned that pregnant women could be infected if they had sexual intercourse with an infected person and that this could be avoided using condoms.

I know that (Zika) is transmitted by the mosquito, that is the main thing, and that we have to pay attention if we have the basins, if we have plants and barrels, we have to keep them clean to avoid larvae and mosquitos at our houses (Focus Group, Women, Hospital).

However, from rounds one to three of survey, the number of participants who also knew of the possible sexual transmission of Zika, decreased (in correlation with distance in time with the outbreak).

Participants mentioned that Zika infection was associated with serious risks for pregnant women. Most mentioned that the baby could get sick, die in the womb, have problems in the head and brain; suffer from microcephaly. Fewer mentioned the Guillain-Barr syndrome and malformations. There was confusion among participants about the difference among Dengue, Chikungunya and Zika infections. For them, the three diseases had the same symptoms and consequences in men or in non-pregnant women. This perception didnt change in the different rounds of interviews.

Well, Ive heard that it affects people, pregnant women, and the baby. When someone is infected, they can infect the baby and cause complications (Focus Group, Women, Hospital).

We must be careful, if we are pregnant, we should be especially careful of not getting a bite, because the baby could be affected. (Focus Group, Women, Hospital).

Most frequently mentioned sources of information were television and radio, followed by Facebook and informative posters at health facilities. During round one of data collection, participants recalled having received information through mass or social media on how to avoid or control mosquitos at home and recalled having seen images of babies with microcephaly.

What I know is how to prevent the disease, but not how to take care of oneself once you get the disease; most of all I know about prevention, that includes a clean household and getting rid of all possible mosquito breeding places and that is what they mainly talk about in the news (Focus Group, Women, Hospital).

Health professionals were the most reliable source of information. However, at the last round of survey, at the end of epidemic, fewer participants received information or noticed any brochures or posters at the health facilities.

Information on Zika is only available when there is an outbreak, they give information to prevent the disease. Why is information available only during outbreaks? (Focus Group, Men, Hospital).

Participants mentioned that they knew of some preventive measures mostly related to the vector transmission; such as covering the water tank (called pila) and cleaning it; however, the information on the frequency of cleaning was not clearly communicated.

We should wash well the sink with chlorine, if you see a tire there with water you must empty it, if you have a leak, or containers full of water they have to be emptied, because that is where the mosquito comes from, wash all the ditches, everything has to be cleaned as much as possible (Focus Group, Women, Hospital).

They knew to use repellents, mosquito nets and coils, and cut tall grass and bushes. Less frequent practiced methods were covering buckets, cleaning gutters, or using a fan to repel mosquitos. Aside from the measures they knew of, participants explained they cleaned their house, and used larvicide and bleach in water tanks. However, many participants were against burning mosquito-repelling incense indoors because the smoke caused cough. Of note, by the third round of interviews, participants stressed that actions performed by public and technical teams in the prevention of Zika in neighbourhoods had ceased.

Upon suspicion of Zika, few participants sought care at a health centre and were referred to a hospital to confirm the diagnosis. However, not everyone attended a health centre; some were diagnosed by a relative who knew of the disease and its symptoms. Moreover, these patients acknowledge they were self-medicated with acetaminophen and liquids, because they knew how physicians treated other cases of Zika infection.

The process for women receiving PAC services at the Gynaecology and Obstetrics Emergency Room at the hospital is described in Fig.2.

Trajectory of women treated for post abortion care at the Gynaecology and Obstetrics Emergency Room and areas for improvement, Hospital, Tegucigalpa, Honduras, 2018

Women seek emergency obstetric care because either they are referred by a health centre or hospital to manage symptoms such as bleeding or pain; or because they are following up treatment with the drug misoprostol (A). Someone (partner, relative, etc.) may or may not accompany them to hospital (B). Those accompanying the women are not allowed inside the premises of the hospital. At the entrance of emergency gate, women are searched by security personnel and then escorted to a waiting area; those who are not ambulatory are assisted by hospital assistants in wheelchairs. In the waiting area, medical students interview the patients and refer them to specific services. Women needing PAC services are admitted to the Gynaecology and Obstetrics Emergency Room (C). Women in emergency are attended round the clock and those with suspected pregnancy are offered pregnancy test (rapid test).

Physicians register patients data and this registry is completed and collected daily by the statistics department. Misoprostol is prescribed and ultrasound is performed on all women. Patients under observation receive family planning counselling in the same room.

Women when referred, are warned that reaching hospital could take them up to two hours, or even more if transportation was unavailable. Participants complained that no other public hospitals offered PAC and highlighted the need for these services to be closer to their homes.

I decided to come today because I was bleeding so much, I fainted, had cold sweats, nausea and my body was shaking (Interview, Woman with MVA procedure, Hospital).

Women had to cover the transportation cost to the only hospital that offered PAC services in the city, and had to pay 200 Lempiras (approx. US$8) per treatment. However, it could reduce to 50 Lempiras (approx. US$2) if social services office certified that the patient could not afford the full fee. Moreover, the hospital also required the patients to bring a gallon of water to clean the medical equipment.

Some patients had to pay for their medication and most women paid for a rapid pregnancy test. It was mentioned that misoprostol, anti-inflammatory agents and analgesics were not freely available; instead, patients had to buy them out-of-pocket. Many times, these payments for specific treatments were out of reach of patients.

They asked me to buy a pregnancy test. Afterwards when they were about to perform the MVA they told me that I had to pay 200 Lempiras and purchase a container of water. (Interview, Woman, Hospital).

By the final round of this survey, following discussion of research team with health authorities, this requirement and the fee was eliminated. The hospital administration purchased a water filter system for emergency room and medical staff with research studys funds.

Participants complained that male partners and relatives were not allowed into the hospital and had to wait long hours without any protection from the weather; slept on the floor at night and received no updates on the health of their partners from physicians or nurses.

The cleaners just started to throw water on the floor, they didnt mind if I had my clothes there or if I was sitting there. I was sitting there, after two nights without any sleep, I fell asleep on my bags on the floor and when I woke up because someone told me to, they were throwing water at me (Interview, Man, Hospital).

Women seeking for emergency care remained unaccompanied in the waiting area and during the procedure.

Through emergency, I got her [wife] in and the guard treated me badly because I came with her and he told me that I couldnt go in and I told him that it was an emergency because she was my wife and she was really sick and had problems. (Focus Group, Men, Hospital).

A very common complaint during the first round was the lack of privacy for the women who sought assistance or during a procedure, including the lack of sufficient beds or rooms. Most participants complained that the admission process was disorganised, difficult and time-consuming, the public toilets were unclean, and medications were often lacking.

The reproductive health counselling was only given after MVA procedures were performed, with no privacy and in the presence of other patients. Over time, participants acknowledged some improvements specially ward cleanliness.

Many participants agreed they had been mistreated by physicians and nurses when seeking PAC or emergency care. Some of the women felt that they were laughed at, reprimanded and ignored by both physicians and nurses.

Today, I was undergoing the MVA, the doctor was doing the procedure with people standing by the door, there was a student asking one thing and another and doctors phone kept ringing. (Interview, Woman, Hospital).

The most common complaint was the staffs lack of empathy and indifference to their health situation.

My mom asked for information because when I was in the ward and there were many girls who had had an abortion and they told me you have to rest, you cant crouch, you cant travel. So, I told mom to get information. The first time I had an abortion, they didnt explain anything to me, they just told me go away and take care!, just that. So, my mom asked a nurse and she just said I had to rest, just that (Focus Group, Women, Hospital).

Accompanying male partners and female patients described instances of mistreatment by the security staff when being admitted to the hospital. The male partners mentioned that they did not receive information about the patients health and procedures during in-hospital stay, the remarked they feel mistreated and that produced distress and fear.

My partner was being accompanied by her sister. I could not get in touch with my partner, I could not even call her on the cell phone. Then, I could talk to her sister, she called me, she was crying and told me that my babys heart was not beating and the doctors had performed an ultrasound and had seen my baby was dead and that they going to do another ultrasound (Interview, Man, Hospital).

Some women complained of having to wait for long hours in pain, only to receive what they perceived as unsatisfactory care. Some women who were prescribed misoprostol felt that they had been discharged without adequate information as they felt staff did not sufficiently explain the procedures to them. Some patients reported that physicians did not treat and even ignored the symptoms they complained about, in particular, pain. After unsuccessful treatment in their own home, some participants had to return to hospital for treatment.

It is a horrible sensation, because one feels as if they are pulling the uterus and the doctors only tell us to cooperate but that is, it is impossible to stay relaxed, when one is going through something so painful. (Interview, Woman, Hospital).

Read the rest here:
Contraception and post abortion services: qualitative analysis of users' perspectives and experiences following Zika epidemic in Honduras - BMC Blogs...

We know that dogs can be diagnosed with brain tumours however this is the first time we have reported on positive results in a preliminary brain cancer study for the treatment of dogs. Animal Life Sciences, Inc. (ALS), a pharmaceutical and nutritional development company announced that a comparative oncology trial being conducted using ALS101( a combination of two brain cancer drug candidates ALS licensed for use in animals) is showing promise in dogs suffering from malignant gliomas, including glioblastoma. Dogs suffer from these same types of aggressive tumours and treatment options, much like those for humans, are extremely limited. ALS have seen regression of tumour in a significant population of dogs treated in a formal Phase I clinical trial and while the tumour did not quite disappear, in some cases it shrank more than 95 percent and the animals lived longer.

News from Sweden now where a study has shown that one year after the diagnosis of low-grade malignant brain tumour just under three people in ten were in full-time employment. For this young patient group, returning to work is a key health factor however another year later, the proportion remained below half. For those of you unsure about the characterisation of a low grade, malignant tumour it is defined in this study as a low-grade glioma which is incurable and grows slowly but, thanks to modern treatments, its survival expectancy has successively increased. Given the patients' low age -- averaging 40 years when they fell ill -- their work capacity is seen as an especially important factor in quality of life. Being able to work again is, for many, a crucial aspect of returning to a normal life.

We have explained about orphan drug diagnosis in these updates before but to recap, in the US the Orphan Drug Act (ODA) provides for granting special status to a drug to treat a rare disease or condition. Benefits for a pharma company of having a drug given orphan designation include tax credits of 50% off the clinical drug testing cost awarded upon approval and eligibility for market exclusivity for 7 years post-approval.

Plus Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for its lead investigational drug, Rhenium NanoLiposomes (RNL) for the treatment of patients with recurrent glioblastoma. RNL is designed to safely, effectively, and conveniently deliver a very high dose of radiation - up to 25 times greater concentration than currently used external beam radiation therapy - directly into the brain tumour for maximum effect. Dr. Marc Hedrick, President and Chief Executive Officer of Plus Therapeutics said: We believe RNL has the potential to prolong survival for patients with malignant brain tumours and that of other difficult to treat radiosensitive tumours.

In the fight against cancer, scientists have long grappled with the ambiguous nature of stem cells. GBM tumours consist of stem cells which have the ability to self-renew making these tumours notoriously hard to treat with targeted radiation therapy and difficult to permanently remove through surgery. However, could gene therapy provide a potential breakthrough in brain cancer treatment and put the invincibility of tumour stem cells into question. This recent paper details a new technique of sensitizing stem cells to radiation therapy, thereby increasing the therapys efficacy.

You may find this overview of dendritic cell vaccines for brain tumours is helpful reading before moving onto this paperOnce, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. John Sampson, M.D., Ph.D. from Duke University a leader in cancer immunotherapy for brain tumours commented on the paper saying These study results not only advance our understanding of a virus role in cancer, but they also signal tremendous hope to patients and their families suffering from this devastating disease

An optimistic-sounding end to this weeks worldwide research update.

Related reading:

If you found this story interesting or helpful, sign up to our weekly e-newsand keep up to date with all the latest from Brain Tumour Research.

Originally posted here:
Treating dogs diagnosed with GBM, getting Swedish patients back to work, orphan designation for improved radiotherapy drug plus gene therapy - Brain...

Sarepta has gone all-in on gene therapy over the last few years, racing with Pfizer and Solid Biosciences to be the first to develop a genetic fix for Duchenne muscular dystrophy, one of the most common rare diseases.

Sarepta has been comfortably in the lead, collecting the first positiveresults and snaring a $1.15 billion cash commercialization deal with Roche, but this week the company hit a snag. Late yesterday, Sarepta provided a program update for its gene therapy, revealing that in a scheduled meeting the FDA had raised concerns about the kinds of tests they would use to measure potency in the pivotal study and commercial supply for the gene therapy. The company has assays that might fit the criteria, they said, but needed additional dialogue with the agency to confirm.

Unlock this story instantly and join 89,800+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Read more here:
FDA knocks back Sarepta in Duchenne gene therapy race with Pfizer, but analysts urge caution - Endpoints News

RESEARCH TRIANGLE PARK Dont call it AveXis anymore. Its now Novartis Gene Therapies.

Novartis has announced the renaming of its previously acquired AveXis gene therapy arm because of the growing importance of gene therapy to building a leading, focused medicines company with advanced therapy platforms.

AveXis, headquartered in Bannockburn, Illinois, was purchased in 2018 for $8.7 billion by the Swiss drugmakerNovartis.

The company announced early last year that it would put $60 million more into its then-new $55 million Durham County manufacturing facility, doubling the workforce here from 200 to 400. Now, according to a Novartis spokesperson, there are more than 400 people working at the Durham site, and more are being hired while the site is anticipating final FDA operational approval in 2021.

The company makes gene therapies for neurological genetic diseases. Its initial product is Zolgensma (onasemnogene abeparvovec-xioi), a gene replacement therapy to treat spinal muscular atrophy (SMA) Type 1, a deadly neuromuscular disease with limited treatment options.

AveXispurchased rightsto its gene therapy technology in 2015 for an undisclosed sum fromAsklepios BioPharmaceutical, a Chapel Hill gene therapy platform company commonly called AskBio.

AskBio said it received an upfront payment and stands to gain milestone payments and royalties based on AveXis successful development and commercialization of its treatment.

AskBios gene therapy platform is based on the work of Jude Samulski, Ph.D., a pioneering scientist in gene therapy who was recruited to the University of North Carolina School of Medicine from the University of Pittsburgh in 1993 with the help of about $250,000 in grant funding from the North Carolina Biotechnology Center. Samulski, renowned for his development of the harmless adeno-associated virus (AAV) as a vector, or delivery tool, for genes, directed UNCs Gene Therapy Center for many years.

Building on the success of Zolgensma, Novartis Gene Therapies said it will be responsible for the research, development, manufacturing and commercialization of the next wave of AAV-based innovative gene therapies. Novartis Gene Therapies will also provide manufacturing support for gene therapy work conducted by other Novartis units.

DavidLennon, Ph.D., previously president of AveXis, is now president of Novartis Gene Therapies and will continue reporting to Vas Narasimhan, CEO of Novartis.

Novartis sees tremendous potential in the future of gene therapy, and weve seen the impact gene therapy can have on so many lives, said Narasimhan. With the creation of Novartis Gene Therapies, we will continue to advance our gene therapy pipeline for rare genetic diseases, to accelerate the delivery of transformative innovation in areas of high unmet need, and to reimagine medicine for patients all around the world.

The most widely used gene therapy in the world, Zolgensma treats SMA, the leading genetic cause of infant death. If left untreated in its most common form, SMA leads to death or the need for permanent ventilation by the age of 2 in more than 90% of cases.

To date, more than 600 patients have been treated with Zolgensma, including in clinical trials, commercially and through managed access programs. In addition to Zolgensma being approved in the U.S., its approved in Japan, Europe and Brazil.

Novartis Gene Therapies is pursuing Zolgensma registration in close to three dozen countries with regulatory decisions anticipated in Switzerland, Canada, Australia, Argentina and South Korea in late 2020 or early 2021.

Novartis said the change to Novartis Gene Therapies is the natural evolution as the company scales up to deliver Zolgensma globally and expand its reach via a robust pipeline of AAV-based gene therapies for rare genetic diseases including investigational treatments for Rett syndrome, a genetic form of amyotrophic lateral sclerosis (ALS) and Friedreichs ataxia.

Novartis Gene Therapies also establishes a seamless global presence for Zolgensma and the gene therapies to come. Instead of alternating between the AveXis and Novartis umbrella brands by market, the company comes together under one banner as a unified entity.

Our patients and their families are the motivation for everything that we do, and under the banner of Novartis Gene Therapies, our dedicated team will continue to create a lifetime of possibilities to people suffering from rare genetic diseases, said Lennon.

Becoming Novartis Gene Therapies symbolizes the importance of our gene therapy advances for the future of Novartis and our industry leadership at large.

Novartis Gene Therapies comprises more than 2,000 employees across corporate, manufacturing and research facilities in the U.S. (Illinois, North Carolina, Colorado, California); Zurich, Switzerland; and Tokyo. With nearly 1 million square feet of gene therapy manufacturing capacity, Novartis Gene Therapies is the worlds largest gene therapy manufacturer.

(C) N.C. Biotech Center

Read the original:
Novartis Gene Therapies is new name for gene therapy firm with growing RTP presence - WRAL Tech Wire

In nearly 40 years of the HIV epidemic, only two people have likely been cured of the virus. Both scenarios resulted from stem cell transplants needed to fight blood cancers such as leukemia. Inspired by these two cases, a team of scientists is studying a multipronged way to potentially control HIV without medication. It involves two different genetic alterations of immune cells and with a safer method of stem cell transplants, also referred to as bone marrow transplants, a procedure that is generally toxic and dangerous.

The research is being funded by a five-year $14.6 million grant from the National Institutes of Health. The scientists coleading the preclinical studies are Paula Cannon, PhD, a distinguished professor of molecular microbiology and immunology at the Keck School of Medicine of the University of Southern California, and Hans-Peter Kiem, MD, PhD, who directs the stem cell and gene therapy program at the Fred Hutchinson Cancer Research Center, also known as Fred Hutch. According to a Keck School of Medicine press release, the two other main partners are David Scadden, MD, a bone marrow transplant specialist and professor at Harvard University and the Harvard Stem Cell Institute, and the biotechnology company Magenta Therapeutics.

In the HIV cure scenariosinvolving the so-called Berlin and London patientsboth men received stem cell transplants from donors with a natural genetic mutation that made them resistant to HIV. Specifically, their genes resulted in immune cells that lack CCR5 receptors on their surface (HIV latches onto these receptors to infect cells). Unfortunately, this method isnt viable for the nearly 38 million people worldwide living with HIV. Not only is it expensive, toxic and riskyit involves wiping out the patients immune system and replacing it with the new immune cellsbut it also requires matched donors who are CCR5 negative. According to the press release, about 1% of the population have this mutation.

With funding from this new grant, researchers hope to overcome these challenges in several ways. First, Cannon has already developed a gene-editing method to remove the CCR5 receptors from a patients own stem cells. She now hopes to further genetically engineer stem cells so they release antibodies that block HIV.

Our engineered cells will be good neighbors, Cannon said in the press release. They secrete these protective molecules so that other cells, even if they arent engineered to be CCR5 negative, have some chance of being protected.

Fred Hutchs Kiem will use CAR-T therapya new method of genetically modifying immune cells that is emerging out of cancer researchwith the goal of creating T cells that attack HIV-infected cells.

In addition, other scientists involved in the federal grant aim to develop less toxic methods of bone marrow transplantationfor example, by reducing the amount of chemotherapy required and speeding up the process of creating the new immune system.

The research finding could translate to other illnesses, such as cancer, sickle cell anemia and autoimmune disorders.

A home run would be that we completely cure people of HIV, Cannon said. What Id be fine with is the idea that somebody no longer needs to take anti-HIV drugs every day because their immune system is keeping the virus under control so that it no longer causes health problems and, importantly, they cant transmit it to anybody else.

For the latest on the cure cases, see Famed London Man Probably Cured of HIV from earlier this year. And in related news, see $14M Federal Grant to Research CAR-T Gene Therapy to Cure HIV.

See the original post:
$14.6M Grant to Explore a Therapy to Control HIV Without Meds - POZ

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. Kenneth Hillan, an accomplished biotechnology executive, to the Company's Board of Directors.

"We are pleased to welcome Kenneth to the Sangamo Board of Directors," said Sandy Macrae, Chief Executive Officer of Sangamo. "We believe that Kenneths 25 years of clinical development and executive leadership experience, as well as his current focus on the therapeutic applications of DNA sequencing data, will provide great benefit to Sangamo as we continue to advance our growing pipeline of genomic medicines through clinical development.

Since 2019, Dr. Hillan has served as Head of Therapeutics of 23andMe, the consumer genetics and research company, leading a dedicated discovery research and therapeutic development team that uses human genetic data to identify and pursue novel therapies for common and rare diseases. Previously, Dr. Hillan held leadership roles in the biotechnology industry. He served at Genentech from 1994 to 2011, where he led the medical and scientific strategies for its Immunology, Tissue Growth and Repair drug portfolio, and held a number of key leadership positions in research and development, including Senior Vice President of Clinical Development, Inflammation; Vice President of Immunology, Tissue Growth and Repair; Vice President of Development Sciences; and Vice President of Research Operations and Pathology. He also served as Genentechs Senior Vice President and Head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in Shanghai, China. From 2011 to 2017, he was Chief Executive Officer of Achaogen, Inc., where he was also a member of the Board of Directors. He has also served on the Board of Directors of Zymeworks since February 2017, and was a member of the Board of Directors of Relypsa from 2014 until 2016, when it was acquired by Galenica AG.

Dr. Hillan has an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, U.K. He is a Fellow of the Royal College of Surgeons (FRCS, Glasg), and a Fellow of the Royal College of Pathologists (FRCPath). Dr. Hillan has authored dozens of scientific publications and is a named inventor on almost 50 issued patents.

Sangamo also today announced that Stephen Dilly, M.B.B.S., Ph.D. will resign from the Board of Directors effective September 30, 2020.

It has been a great pleasure serving as a Sangamo director for the past decade, said Dr. Dilly. With a broad therapeutic pipeline, meaningful collaborations with global biopharmaceutical companies, and a strong balance sheet, Sangamo is well positioned as a leader in the field of genomic medicine. I'm personally very pleased to welcome Kenneth Hillan to the Board and am excited for the future success of Sangamo."

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and genome regulation. For more information about Sangamo, visit http://www.sangamo.com.

Forward Looking Statements

This press release contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize therapies to treat genetic diseases and the timing thereof, the anticipated benefits of Sangamos collaborations, Sangamos financial resources and expectations and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the operations and business environments of Sangamo and its collaborators. These risks and uncertainties are described more fully in Sangamo's Securities and Exchange Commission filings and reports, including in Sangamos Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

See the rest here:
Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors - Business Wire

After immune modulators and antibodies, blood thinners are the next class of drugs to be put through a Phase III trial organized under the NIHs ACTIV initiative.

Three different anticoagulants have been named for the master protocol: heparin, aspirin and apixaban. Informed by studies suggesting that many patients who died from Covid-19 have formed unusual blood clots throughout their bodies including in their smallest blood vessels the NIH wants to see which therapies are the most effective at preventing or reducing them and thus improving outcomes for patients.

There is currently no standard of care for anticoagulation in hospitalized COVID-19 patients, and there is a desperate need for clinical evidence to guide practice, agency head Francis Collins said in a statement. Conducting trials using multiple existing networks of research sites provides the scale and speed that will get us answers faster.

For the inpatient trial, patients will be given either a low dose or a high dose of heparin.

But hospitalized patients are just one of two groups now being recruited to ACTIV-4, which also includes an outpatient trial broken down into four cohorts given placebo, aspirin, or a low or therapeutic dose of the blood thinner apixaban. The goal there is to reduce life-threatening cardiovascular or pulmonary complications in newly-diagnosed Covid-19 patients who dont need hospital admission.

Gary Gibbons, director of the National Heart, Lung, and Blood Institute, said while heparin has shown promise, physicians really need clinical trial data to determine how much blood thinner, or even anti-platelet medication, to give.

A third trial will start soon involving patients who had moderate or severe disease but have been discharged after hospitalization. It has a slightly different design, with the key metric being whether patients develop thrombotic complications (think heart attack, stroke, blood clots in major veins or arteries and death) within 45 days of being hospitalized.

As is custom in these master protocols, researchers may switch out candidates or add in new therapies as clinical data emerge.

NHLBI is coordinating and overseeing the program, while Operation Warp Speed is providing the funding. Amber Tong

The JP Morgan Healthcare Conference just got a whole lot cheaper.

On Thursday, the bank told clients that the famed conference was going virtual. That means no more packing into ballrooms and conference halls, no more dashing between different hotel rooms for an endless circle of meetings, and crucially no more $2,000 suites and $150 rent-a-tables. Instead, there will only be what there has been for the last 6 months: Endless circles of Zoom meetings, looped in infinite recursion from San Diego to Boston to Cambridge, UK.

The virtual conference means that, after years of chatter, the conference will finally, at least for a year, leave San Francisco. In theory, though, you could still go. A room at the Westin is selling for only $276, breakfast not included. Jason Mast

Longtime FDA officials and drug companies are trying to shore up public confidence in an eventual Covid-19 vaccine, but a new poll suggests that, at least until the election, they could be facing an uphill battle.

The poll, conducted by theKaiser FamilyFoundation,found that most adults, both Republican and Democrat, are wary of taking a vaccine before the election. Six in ten adults, meanwhile, were worried that the Trump Administration would pressure the FDA to rush an approval. The poll was conducted between August 28 and September 3 days after a heavily politicized emergency use authorization for convalescent plasma stoked fears that a vaccine would be authorized under similar conditions.

Fear of political pressure was most acute among Democrats, 51% of whom said they were very worried and 85% of whom were at least somewhat worried. A majority of Republicans said they were not too worried or not at all worried, although 35% expressed some concern.

As to whether they would take a vaccine, though, the splits are reversed. Half of Democrats were willing to take a vaccine, but only 36% of Republicans said they would. These numbers are in linewith long-running differences between Democrats and Republicans on vaccination, though it does suggest that recent events may have dented views. A Gallup pollconducted in late July and early August found 81% of Democrats and 47% of Republicans were willing to take an an FDA-approved vaccine to prevent coronavirus/COVID-19 if it was available right now at no cost. Those questions, though, did not directly reference the election.

Still, most respondents did not think such an eventuality was likely. Eighty-one percent of people, regardless of party, did not expect a vaccine to come before November 3.

The polls come as officials in the US struggle to shore up confidence in any eventually approved vaccine. Earlier this week, 9 major drug companies signed a pledge to only submit vaccine data when it meets safety and efficacy standards and 8 FDA career officialspublishedan open letter in USA Today on their commitment to science. Even before the latest concerns of political interference, public health experts have talked for months about how rising rates of vaccine hesitancy could pose a barrier in pandemic response. Bill Gates has called getting people to actually take a vaccine the final hurdle.

New data highlight how criticalmessaging can be on vaccine uptake. A large study published this morning inThe Lancettracked global vaccine hesitancy from 2015 to 2019 identified misinformation as one of the key factors in places with growing skepticism of vaccines, including South Korea, Malaysia, and Georgia. Anthropologist and director of the Vaccine Confidence Project Heidi Larson, the studys author, said messaging in the US and elsewhere that focused on speed wasnt helping.

Theres a lot of anxiety about the speed of vaccine development (for COVID-19), she told Reuters. But the public is not really keen on speed theyre more keen on thoroughness, effectiveness and safety. Jason Mast

For a look at allEndpoints Newscoronavirus stories, check out ourspecial news channel.

See original here:
Covid-19 roundup: NIH spotlights blood thinners in its next big trial; All it took was a pandemic to get JPM out of SF - Endpoints News

Boehringer Ingelheim wants in on digital therapeutics.

The German pharma signed an up to $500 million collaboration with Click Therapeutics, one of a handful of major companies developing prescription computer and smartphone applications for various neurological or mental disorders. They join a small list of pharmas that have decided to test the waters in the emerging field.

Under the deal, Boehringer and Click will co-develop a digital therapeutic for schizophrenia, known as CT-155. Its a complementary effort to Boehringers more traditional schizophrenia work. The company has concentrated their neuroscience efforts there since 2018, when a Phase II failure blew up their late-stage Alzheimers efforts.

CT-155 is an excellent addition to our CNS pipeline portfolio; it reflects our patient centric approach and translates evidence showing how behavioral modification can induce positive neuronal changes into a widely accessible solution,Cornelia Dorner-Ciossek, Boehringers head of CNS disease research, said in a statement.

Boehringer is at least the third Big Pharma to dip their toes into digital therapeutics. Sanofi Ventures the French giants investment arm led a $17 million funding round for Click in 2018, the same year Mercks venture arm contributed to the video game therapeutics company Akilis $55 million Series C. Novartis also signed a partnership that year with Pear Therapeutics to commercialize Pears FDA-authorized app for substance abuse, although they pulled out of the partnership just one year later.

Boehringers new deal marks one of the first major development partnerships between a large pharma company and a digital therapeutic.

Click has already developed a commercial app for smoking cessation called Clickotine. Clickotine, like the other apps Click has in development for insomnia, migraine and major depressive disorder, among others, uses a variety of smartphone-based features to try to adjust peoples behavior. In Clickotines case, that involves personalized curriculums that offer users live coaching, guided breathing, and personal analytics. That app, though, while backed by a non-controlled study, did not have to be FDA-approved as other apps will.

Click has released little about CT-155 its description on their website reads simply confidential but in theory it could be used alongside existing schizophrenia drugs and, eventually, alongside the schizophrenia meds Boehringer now has in its pipeline. Two such compounds are now in Phase II.

Read the original post:
After Novartis left, Boehringer bets up to $500M on the field of prescription smartphone apps - Endpoints News

Xtalks Life Science Webinars

TORONTO (PRWEB) September 11, 2020

During the last five years, the number of cell and gene therapies (CGT) have exponentially increased, stimulated by their efficacy and potential for cure. However, CGT can expose the patients to significant toxicities such as cytokine release syndrome (CRS) and neurotoxicities (ICANS), requiring specialised and accurate management associated with precise data capture and analysis. Timely and unrestricted support is crucial for the safe progress of CGT. In addition, dealing with these living therapies represents whats been called the most complex supply chain in the history of medicine.

This webinar will present and discuss the challenges involved in supporting CGT-related clinical trials. Attendees will gain first-hand learning from members of a multidisciplinary team that was developed at ICON for the successful support of CGT clinical trials.The participants will learn the following during the presentation:

A The medical landscape:

B Operational management:

C Commercialisation and logistics

Join Anne S. Renteria, MD, Medical Director, Medical Affairs, ICON plc, Brandon Fletcher, PhD, Principal, Clinical Project Management, ICON plc and Tamie Joeckel, Business Lead, Cell and Gene Therapy Center of Excellence, ICON plc in a live webinar on Thursday, September 24, 2020 at 10am EDT (3pm BST/UK).

For more information or to register for this event, visit Achieving Quality Cell and Gene Therapies Outcomes Through Multidisciplinary Collaboration.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.comFor information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Follow this link:
Achieving Quality Cell and Gene Therapies Outcomes Through Multidisciplinary Collaboration, Upcoming Webinar Hosted by Xtalks - PR Web

While there is no cure for blindness and macular degeneration, scientists have accelerated the process to find a cure by visualizing the inner workings of the eye and its diseases at the cellular level.

In an effort led by UW Medicine, researchers successfully modified the standard process of optical coherence tomography (OCT) to detect minute changes in response to light in individual photoreceptors in the living eye.

The results were published Sept. 9 in Science Advances.

"We have now accelerated the life cycle of vision restoration," said lead author Vimal Prabhu Pandiyan, a ophthalmology researcher at the University of Washington School of Medicine.

The study was funded in part by the National Eye Institute's Audacious Goals Initiative, which embraces bold ideas in helping people to see better.

The OCT modifications outlined in the study will help researchers who want to test therapies such as stem cells or gene therapy to treat retinal disease. They now have the tools to zoom in on the retina to evaluate whether the therapy is working.

Corresponding author Ramkumar Sabesan, a UW assistant research professor of ophthalmology, said the only way to objectively measure the eye currently is to look at a wide retinal area. Sabesan said researchers currently can attach electrodes on the cornea but it captures a large area with around 1 million cells. Now they are talking about nanometers, or one billionth of a meter - a small fraction of the size of a cell, providing orders of magnitude improvement.

"Since photoreceptors are the primary cells affected in retinal generation and the target cells of many treatments, noninvasive visualization of their physiology at high resolution is invaluable," the researchers wrote.

Cone photoreceptors are the building blocks of sight, capturing light and funneling information to the other retinal neurons. They are a key ingredient in how we process images and patterns of light falling on the retina.

Optical coherence tomography has been around since the 1990s. In this study, researchers used OCT with adaptive optics, line-scanning and phase-resolved acquisition to deliver the concept of Thomas Young's interference to the human eye. With the ability to zoom in on the retina at high speeds, they found that cone photoreceptors deform at the scale of nanometers when they first capture light and begin the process of seeing.

As Sabesan explained: "You can imagine a picture that looks visually and structurally normal. But when we interrogate the inner working of the retina at a cellular scale, we may detect a dysfunction sooner than what other modalities can do. A doctor then can prescribe medication to intervene early or follow the time-course of its repair via gene therapy or stem cell therapy in the future."

"We will now have a way to see if these therapies are acting in the way they should," Sabesan said.

Read more:
Seeing the eye like never before - Science Codex

One of many major challenges facing gene therapy a approach to deal with illness by changing a affected persons faulty genes with wholesome ones is that its troublesome to securely ship therapeutic genes to sufferers with out the immune system destroying the gene, and the car carrying it, which might set off life-threatening widespread irritation.

Three a long time in the past researchers thought that gene remedy can be the last word remedy for genetically inherited illnesses like hemophilia, sickle cell anemia, and genetic illnesses of metabolism. However the know-how couldnt dodge the immune response.

Since then, researchers have been searching for methods to good the know-how and management immune responses to the gene or the car. Nevertheless, lots of the methods examined to date have not been completely successful in overcoming this hurdle.

Medicine that suppress the entire immune system, similar to steroids, have been used to dampen the immune response when administering gene remedy. However its troublesome to regulate when and the place steroids work within the physique, they usually create undesirable unwanted side effects. My colleague Mo Ebrahimkhani and I wished to deal with gene remedy with immune-suppressing instruments that have been simpler to regulate.

I am a medical doctor and synthetic biologist involved in gene remedy as a result of six years in the past my father was recognized with pancreatic cancer. Pancreatic most cancers is without doubt one of the deadliest types of most cancers, and the at present out there therapeutics often fail to avoid wasting sufferers. Consequently, novel therapies similar to gene remedy could be the one hope.

[Learn: These tech tendencies outlined 2020 to date, in keeping with 5 founders]

But, many gene therapies fail as a result of sufferers both have already got pre-existing immunity to the car used to introduce the gene or develop one in the midst of remedy. This downside has plagued the sector for many years, stopping the widespread utility of the know-how.

Historically scientists use viruses from which harmful disease-causing genes have been eliminated as automobiles to move new genes to particular organs. These genes then produce a product that may compensate for the defective genes which might be inherited genetically. That is how gene remedy works.

Although there have been examples displaying that gene therapy was helpful in some genetic illnesses, theyre nonetheless not good. Generally, a defective gene is so large that you couldt merely match the wholesome alternative within the viruses generally utilized in gene remedy.

One other downside is that when the immune system sees a virus, it assumes that its a disease-causing pathogen and launches an assault to battle it off by producing antibodies and immune response simply as occurs when individuals catch another infectious viruses, like SARS-CoV-2 or the frequent chilly.

Not too long ago, although, with the rise of a gene-editing technology called CRISPR, scientists can do gene remedy otherwise.

CRISPR can be utilized in some ways. In its main function, it acts as a genetic surgeon with a pointy scalpel, enabling scientists to discover a genetic defect and proper it throughout the native genome in desired cells of the organism. It might probably additionally restore multiple gene at a time.

Scientists can even use CRISPR to show off a gene for a brief time frame after which flip it again on, or vice versa, with out completely altering the letters of DNA that makes up our genome. Which means that researchers like me can leverage CRISPR know-how to revolutionize gene therapies within the coming a long time.

However to make use of CRISPR for both of those features, it nonetheless must be packaged right into a virus to get it into the physique. So some challenges, similar to stopping the immune response to the gene remedy viruses, nonetheless have to be solved for CRISPR-based gene therapies.

Being educated as a synthetic biologist, I teamed up with Ebrahimkhani to make use of CRISPR to check whether or not we may shut down a gene thats liable for the immune response that destroys the gene remedy viruses. Then we investigated whether or not decreasing the exercise of the gene, and dulling the immune response, would permit the gene remedy viruses to be more practical.

[Deep information, every day. Sign up for The Conversations newsletter.]

CRISPR can exactly take away even single items of DNA. KEITH CHAMBERS/SCIENCE PHOTO LIBRARY/Getty Images

A gene called Myd88 is a key gene within the immune system and controls the response to micro organism and viruses, together with the frequent gene remedy viruses. We determined to briefly flip off this gene in the entire physique of lab animals.

We injected animals with a group of the CRISPR molecules that focused the Myd88 gene and seemed to see whether or not this lowered the variety of antibodies that have been produced to particularly battle our gene remedy viruses. We have been excited to see that the animals that obtained our remedy utilizing CRISPR produced much less antibodies towards the virus.

This prompted us to ask what occurs if we give the animal a second dose of the gene remedy virus. Often, the immune response towards a gene remedy virus prevents the remedy from being administered a number of occasions. Thats as a result of after the primary dose, the immune system has seen the virus, and on the second dose, antibodies swiftly assault and destroy the virus earlier than it could possibly ship its cargo.

We noticed that animals receiving multiple dose didnt present a rise in antibodies towards the virus. And, in some instances, the impact of gene remedy improved in contrast with the animals through which we had not paused the Myd88 gene.

We additionally did plenty of different experiments that proved that tweaking the Myd88 gene might be helpful in combating off different sources of irritation. That could possibly be helpful in illnesses like sepsis and even COVID-19.

Whereas we at the moment are starting to enhance this technique by way of controlling the exercise of the Myd88 gene. Our outcomes, now revealed in Nature Cell Biology, present a path ahead to program our immune system throughout gene therapies and different inflammatory responses utilizing the CRISPR know-how.

This text is republished from The Conversation by Samira Kiani, Affiliate Professor of Pathology, University of Pittsburghbeneath a Artistic Commons license. Learn the original article.

See more here:
How CRISPR is tackling the troubling immune response that's plagued gene therapy until now - Best gaming pro

By Bruce DePuytSeptember 10, 2020

A 2016 decision to link the research labs at the University of Maryland College Park with those at the University of Maryland at Baltimore is paying dividends in the competition for federal COVID-19 research dollars, a top education official told a science advisory panel on Wednesday.

The decision was a spinoff of the University of Maryland Strategic Partnership Act, said Laurie Ellen Locasio, vice president for research at the two institutions.

"Now we'll be ranked together by the [National Science Foundation] in the U.S. rankings of research universities and together this makes us [an] over $1 billion public research enterprise," she told the Maryland Life Sciences Advisory Board.

With a multi-billion dollar research powerhouse, the privately-funded Johns Hopkins University, also operating here, Maryland is unusually well-positioned, Locasio said.

"Very few states in the country have the distinction of having two research universities with over a billion dollars in research spending per year. We've really shown up as central to this pandemic."

Martin Rosendale, the CEO of the Maryland Tech Council, said there are so many therapeutics and vaccines in development that keeping up with them all is a daunting task.

Many firms adopted a "drop everything" approach when the scope of the coronavirus challenge started to become apparent, he said.

"We just saw a lot of amazing thing happening here in Maryland so many companies were pivoting immediately to support the response to the pandemic," he said. "They were basically dropping their other work and on their own dime spending their own money evaluating their technologies, their platforms, how they could apply them to COVID-19."

Many of the big players have grabbed global headlines for their work on a possible vaccine. But smaller companies are making potentially valuable strides as well, Commerce Secretary Kelly M. Schulz told the panel.

Other firms are working to develop COVID tests that are faster and more reliable.

The Tech Council formed the Maryland COVID-19 Coalition to bring companies together, "to make sure they knew who each other were and begin a conversation," Rosendale said. Twenty-five firms were part of the coalition's first call; 40 were on the second.

Chris P. Austin, director of the National Center for Advancing Translation Sciences at NIH, told the panel that the federal government has pumped more than $20 billion into COVID research.

"Of that, we know that over $3 billion is coming here to Maryland," Rosendale said. "That's a testament to the amazing vaccine and cell-and-gene therapy industries that have grown up here."

If foundation and other non-government funds are added to the public dollars, "the number is well over $4 billion," he added.

To play off the capital region's strengths in biotech, a group of industry leaders in Maryland, Washington, D.C., and Virginia is organizing a "pandemic and bio-defense center" to help countries around the globe guard against future pandemics.

"Because of the prominence of what's going on with COVID-19 development in our region especially within Maryland with vaccine, diagnostics, and therapeutic research we are sort of the epicenter in the world right now," said Richard A. Bendis, president and CEO of BioHealth Innovation, Inc. in Rockville.

"People are starting to take notice."

Schulz said the Department of Commerce paused its planned marketing efforts in the spring to focus on the pandemic, but now is ready to gear back up again with an "Innovation Uncovered" campaign.

"We're going back to where we wanted to be at the beginning of the year, which was to push the bio- and the life sciences worlds out, because we have heard from [company executives] that Maryland needs to be seen as a strong, tight ecosystem for this industry," she said.

bruce@maryandmatters.org

For more stories from Maryland Matters, visit http://www.marylandmatters.org.

More here:
Maryland Labs Developing Vaccines And Therapeutics, Attracting Federal Dollars - Patch.com

This report focuses on the Global Gene Therapy Market trends, future forecasts, growth opportunities, key end-user industries, and market players. The objectives of the study are to present the key developments of the market across the globe.

The latest research report on Gene Therapy market encompasses a detailed compilation of this industry, and a creditable overview of its segmentation. In short, the study incorporates a generic overview of the Gene Therapy market based on its current status and market size, in terms of volume and returns. The study also comprises a summary of important data considering the geographical terrain of the industry as well as the industry players that seem to have achieved a powerful status across the Gene Therapy market.

Get Sample of this Premium Report @ https://industrystatsreport.com/Request/Sample?ResearchPostId=579&RequestType=Sample

Gene Therapy Market Segmentation

Reports include the following segmentation: By Disease Indication Cancer Genetic disorders Cardiovascular diseases Ophthalmology Neurological conditions OthersBy Type of Vectors Viral vectors Non-viral vectorsBy Type of Cells Somatic cells Germline cellsBy Region North Americao U.S.o Canadao Mexico Europeo UKo Franceo Germanyo Russiao Rest of Europe Asia-Pacifico Chinao South Koreao Indiao Japano Rest of Asia-Pacific LAMEAo Latin Americao Middle Easto Africa

The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

Global Gene Therapy Market: Competitive LandscapeThis section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2020.

The major players in the market Pfizer Inc. Novartis AG Bayer AG Sanofi GlaxoSmithKline plc. Amgen Inc. Boehringer Ingelheim International GmbH uniQure N.V. bluebird bio, Inc. Celgene Corporation Others

Global Gene Therapy MarketThis research report providesCOVID-19 Outbreakstudy accumulated to offer Latest insights about acute features of the Gene Therapy Market. The report contains different market predictions related to marketsize, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary andSWOT analysis.It presents the360-degreeoverview of the competitive landscape of the industries. Gene Therapy Market is showing steadygrowthandCAGRis expected to improve during the forecast period.

The main sources are industry experts from the global Gene Therapy industry, including management organizations, processing organizations, and analytical services providers that address the value chain of industry organizations. We interviewed all major sources to collect and certify qualitative and quantitative information and to determine future prospects. The qualities of this study in the industry experts industry, such as CEO, vice president, marketing director, technology and innovation director, founder and key executives of key core companies and institutions in major biomass waste containers around the world in the extensive primary research conducted for this study We interviewed to acquire and verify both sides and quantitative aspects.

Global Gene Therapy Market: Regional AnalysisThe report offers in-depth assessment of the growth and other aspects of the Gene Therapy market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.

Do You Have Any Query Or Specific Requirement @https://industrystatsreport.com/Request/Sample?ResearchPostId=579&RequestType=Methodology

Complete Analysis of the Gene Therapy Market:

Comprehensive assessable analysis of the industry is provided for the period of 2020-2025 to help investors to capitalize on the essential market opportunities.

The key findings and recommendations highlight vital progressive industry trends in the global Gene Therapy market, thereby allowing players to improve effective long term policies

A complete analysis of the factors that drive market evolution is provided in the report.

To analyze opportunities in the market for stakeholders by categorizing the high-growth segments of the market

The numerous opportunities in the Gene Therapy market are also given.

Report Answers Following Questions:

What are the factors driving the growth of the market?

What factors are inhibiting market growth?

What are the future opportunities in the market?

Which are the most dynamic companies and what are their recent developments within the Gene Therapy Market?

What key developments can be expected in the coming years?

What are the key trends observed in the market?

TABLE OF CONTENT

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2020-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Read Full Report: https://industrystatsreport.com/Lifesciences-and-Healthcare/Gene-Therapy-Market-Share/Summary

About Us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at sales@brandessenceresearch.com

Blog: https://businessstatsnews.com

Blog: http://www.dailyindustrywatch.com

Blog: https://marketsize.biz

Blog:https://technologyindustrynews.com

Blog: https://marketstatsreport.com

Blog:https://tcbiznews.com/

Top Trending Reports:

https://brandessenceresearch.com/healthcare/bispecific-antibody-market-size

https://www.marketwatch.com/press-release/cryogenic-pumps-market-size-by-2020-2025-manufacturers-advancements-sales-shares-challenges-opportunities-2020-09-10?tesla=y

https://marketstatsreport.com/anti-ageing-drugs-market-2020-global-demand-key-players-overview-supply-and

https://marketstatsreport.com/clindamycin-phosphate-injection-market-global-industry-analysis-size-share-growth-trends-and

https://marketstatsreport.com/global-clindamycin-phosphate-topical-market-2020-top-manufactures-growth-opportunities-and-investment

Originally posted here:
Gene Therapy Market to Eyewitness Massive Growth by 2026: Leading Key Players Pfizer Inc. Novartis AG Bayer AG Sanofi GlaxoSmithKline plc. Amgen Inc....

[190+ Pages PDF Report] Facts & Factors (FnF) published a market research report onCancer Gene Therapy Market: By Size, Share, Growth, Analysis Covering COVID-19 Impact and Forecast to 2020-2026that includes a research report with TOC including a list of tables and figures in its research offerings.

Cancer Gene Therapy Market Market Report: Industry Insights, 2020-2026

This multi-client research study on theCancer Gene Therapy Market marketprovides in-depth research and analysis into Cancer Gene Therapy Market industry trends, market developments and technological insights. The report provides data and analysis of Cancer Gene Therapy Market penetration across application segments across countries and regions. The report presents a strategic analysis of the Cancer Gene Therapy Markety market through key drivers, challenges, opportunities, and growth contributors.

The global Cancer Gene Therapy Market market delivers value to customers through reliable market size for 2020 on the basis of demand and price analysis. The report presents near term and long term forecast of the addressable Cancer Gene Therapy Market market size to 2026.

The report presents an introduction to the Cancer Gene Therapy Market market in 2020, analyzing the COVID-19 impact both quantitatively and qualitatively.

Request an Exclusive FREE SAMPLE REPORT of Cancer Gene Therapy Market Market:https://www.fnfresearch.com/sample/cancer-gene-therapy-market-by-type-ex-vivo-898

(The sample of this report is readily available on request).

The FREE PDF Sample Report Includes:

(Note: The sample of this report is updated with COVID-19 impact analysis before delivery)

Some of Following Top Market Players Profile Included in This Report:

2020 Cancer Gene Therapy Market Market: COVID-19 Impact Analysis

The global rise of COVID-19 has many businesses struggling and confused about what steps to take to minimize the economic impact. A simple look at the stock market will tell you that coronavirus has led to a volatile economy, but there are numerous other factors at play.

The long term COVID-19 impact on the business industry is largely still unknown; hence,Facts and Factors market researchanalysts have already covered the effects of COVID-19 on the business industry at a large level, as well as global and regional levels. Through our coverage below, get a better understanding of the business and economic implications coronavirus has on trends like remote working, consumer shopping behavior, global advertising spend, and essential industries like food, medical, travel, and transportation.

Download the Free Sample Report PDF Brochure Including COVID-19 Business Impact:https://www.fnfresearch.com/sample/cancer-gene-therapy-market-by-type-ex-vivo-898

Cancer Gene Therapy Market Market 2020: Research Scope & Coverage

The report coversCancer Gene Therapy Market market sizeand growth, characteristics, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the markets historic and forecast market growth by geography. The market size analysis gives the market size covering both the historic growth of the market, the impact of the COVID 19 virus, and forecasting its recovery. The report also provides a comprehensive analysis of current & future trends and emerging avenues for the growth of this market along with this research also offers an insight into the competitive landscape in terms of new technological developments, untapped segments, and value chain analysis.

The report, Cancer Gene Therapy Market Market, provides up-to-date information about market size, share shifts, and potential risks, as well as in-depth knowledge of products and services, which can help in planning and in executing category management activities. It focuses on the cost-saving aspects of procurement and on providing insights that can lead to the optimization of category spend.

Get Free Customized Copy of Cancer Gene Therapy Market Market Report @https://www.fnfresearch.com/customization/cancer-gene-therapy-market-by-type-ex-vivo-898

(We customize your report according to your research need. Ask our sales team for report customization.)

Competitive Landscape

The market appears to be fragmented and with the presence of several. Thissize of Cancer Gene Therapy Market marketresearch report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the markets competitive landscape and offering information on the products offered by companies.

Key Takeaways from this Cancer Gene Therapy Market Market Report

About Us:

Facts & Factorsis a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies globally to understand the international and regional business background.

Contact Us (Corporate Office):Facts & FactorsA 2108, Sargam,Nanded City,Sinhagad Road,Pune 411041, IndiaUSA: +1-347-989-3985Email:sales@fnfresearch.comWeb:https://www.fnfresearch.com

Read the original:
Cancer Gene Therapy Market Size Will Expand Post COVID-19 Covered in Forecast Report 2020-2026 - NJ MMA News

Global Coronavirus pandemic has impacted all industries across the globe, Gene Therapy for Ovarian Cancer market being no exception. As Global economy heads towards major recession post 2009 crisis, Cognitive Market Research has published a recent study which meticulously studies impact of this crisis on Global Gene Therapy for Ovarian Cancer market and suggests possible measures to curtail them. This press release is a snapshot of research study and further information can be gathered by accessing complete report. To Contact Research Advisor Mail us @ [emailprotected] or call us on +1-312-376-8303.

The research report on global Gene Therapy for Ovarian Cancer market as well as industry is a detailed study that provides detailed information of major key players, product types & applications/end-users; historical figures, region analysis, market drivers/opportunities & restraints forecast scenarios, strategic planning, and a precise section for the effect of Covid-19 on the market. Our research analysts intensively determine the significant outlook of the global Gene Therapy for Ovarian Cancer market study with regard to primary & secondary data and they have represented it in the form of graphs, pie charts, tables & other pictorial representations for better understanding.

Intravenous, Intratumoral, Intraperitoneal are some of the key types of market. All the type segments have been analyzed based on present and future trends and the market is estimated from 2020 to 2027. Based on the application segment, the global market can be classified into Ovarian Cancer (unspecified), Recurrent Ovarian Epithelial Cancer, Platinum Resistant Ovarian Cancer . The analysis of application segment will help to analyze the demand for market across different end-use industries.

Request Free Sample Copy of Gene Therapy for Ovarian Cancer Market Research [emailprotected] https://cognitivemarketresearch.com/medical-devicesconsumables/gene-therapy-for-ovarian-cancer-market-report#download_report

Amid the COVID-19 pandemic, the industry is witnessing a major change in operations.Some of the key players include Takara Bio, VBL Therapeutics, CELSION, Targovax . key players are changing their recruitment practices to comply with the social distancing norms enforced across several regions to mitigate the risk of infection. Additionally, companies are emphasizing on using advanced recruiting solutions and digital assets to avoid in-person meetings. Advanced technologies and manufacturing process are expected to play a decisive role in influencing the competitiveness of the market players.

Regional Analysis for Gene Therapy for Ovarian Cancer Market:North America (United States, Canada)Europe (Germany, Spain, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, India, Australia, and South Korea)Latin America (Brazil, Mexico, etc.)The Middle East and Africa (GCC and South Africa)

Get A Free Sample of Gene Therapy for Ovarian Cancer Market Report: https://cognitivemarketresearch.com/medical-devicesconsumables/gene-therapy-for-ovarian-cancer-market-report#download_report

NOTE: Whole world is experiencing the impact of Covid-19 pandemic due to its increasing spread hence, the report comprises of an up to date scenario of the Gene Therapy for Ovarian Cancer market report. Research analyst team of our company is understanding & reviewing the Covid19 Impact on Market and all the necessary areas of the market that have been altered due to the change caused by Covid19 impact. Get in touch with us for more precise/in-depth information of the Gene Therapy for Ovarian Cancer market.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here>Download Sample Report of Gene Therapy for Ovarian Cancer Market Report 2020 (Coronavirus Impact Analysis on Gene Therapy for Ovarian Cancer Market)

At the end of May, many states began lifting lockdown restrictions and reopening in order to revive their economies, despite warnings that it was still too early. As a result, by mid-July, around 33 states were reporting higher rates of new cases compared to the previous week with only three states reporting declining rates. Due to this Covid-19 pandemic, there has been disruptions in the supply chain which have made end-use businesses realize destructive in the manufacturing and business process. During this lockdown period, the plastic packaging helps the products to have longer shelf life as the public would not be able to buy new replacements for the expired products because most of the production units are closed.

About Us:Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market.Contact Us: +1-312-376-8303Email: [emailprotected]Web: https://www.cognitivemarketresearch.com/

Read this article:
Global and US Gene Therapy for Ovarian Cancer Market to Witness Huge Growth by abc Major Players included in report Takara Bio, VBL Therapeutics,...

TEL AVIV, Israel, Sept. 11, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today presents for the first time new data demonstrating ex-vivo activity of its proprietary investigational anti-MOSPD2 mAbs in patients with relapsing-remitting and progressive multiple sclerosis (MS). VBL's study is being presented at the MS Virtual 2020, the virtual 8th Joint ACTRIMS-ECTRIMS Meeting.

Data show that VBL's anti-MOSPD2 mAbs significantly inhibited migration of monocytes isolated from all MS patients included in the study (n=33) by up to 97%, regardless of disease severity, gender or active treatment. Notably, the activity was seen not only in the monocytes from relapsing-remitting, but also those from primary progressive and secondary progressive patients with high Expanded Disability Status Scale (EDSS) scores of 5.5-6.5.

We believe our antibodies open up a completely novel mechanism for potential treatment of MS, through blocking the accumulation of monocytes/macrophages in the central nervous system, said Itzhak Mendel, Ph.D., Immunology Director of VBL Therapeutics. This mechanism is differentiated from the existing available treatments, which mostly target T and B cells and therefore, it is not surprising that our antibodies showed activity on top of any patient active therapy. Backed up by strong preclinical results, these first patient-driven proof-of-concept data reinforce the therapeutic potential of our MOSPD2 program.

VBL is currently advancing lead anti-MOSPD2 candidate VB-601 through IND-enabling studies, aiming to start a first-in-human study in 2H 2021.

For a link to VBL's presentation at the MS Virtual 2020 conference, see: LINK

About VBL's VB-600 PlatformVBL is conducting two parallel drug development programs that are exploring the potential of MOSPD2 (motile sperm domain-containing protein 2), a protein that VBL has identified as a key regulator of cell motility, as a therapeutic target for inflammatory diseases and cancer. Our VB-600 platform comprises classical anti-MOSPD2 monoclonal antibodies for inflammatory indications, as well as bi-specific antibody candidates for oncology.

About VBLVascular Biogenics Ltd., operating asVBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBLs lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every 6-8 weeks. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in a VBL-sponsored all comers Phase 1 trial as well as in three VBL-sponsored tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a VBL-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer.

Forward Looking StatementsThis press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as anticipate, believe, could, estimate, expect, goal, intend, look forward to, may, plan, potential, predict, project, should, will, would and similar expressions. These forward-looking statements may include, but are not limited to, statements regarding our programs, including MOSPD2, including their clinical development, therapeutic potential and clinical results. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical clinical trial results may not be predictive of future trial results, the impact of the COVID-19 pandemic on our business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines and clinical results, that our financial resources do not last for as long as anticipated, and that we may not realize the expected benefits of our intellectual property protection. A further list and description of these risks, uncertainties and other risks can be found in our regulatory filings with theU.S. Securities and Exchange Commission, including in our annual report on Form 20-F for the year endedDecember 31, 2019, and subsequent filings with theSEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.VBL Therapeuticsundertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

INVESTOR CONTACT:Michael RiceLifeSci Advisors, LLC(646) 597-6979

The rest is here:
VBL Presents Human Proof-of-Concept Data That Show the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Multiple Sclerosis at the MS...

LOS ANGELES, United States: QY Research as of late produced a research report titled, Global and United States Precision Cancer Therapies Market Size, Status and Forecast 2020-2026. The research report speak about the potential development openings that exist in the worldwide market. The report is broken down on the basis of research procedures procured from historical and forecast information. The global Precision Cancer Therapies market is relied upon to develop generously and flourish as far as volume and incentive during the gauge time frame. The report will give a knowledge about the development openings and controls that will build the market. Pursuers can increase important perception about the eventual fate of the market.

The global Precision Cancer Therapies market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.

Key Companies/Manufacturers operating in the global Precision Cancer Therapies market include: , Abbott Laboratories, Bayer HealthCare, GlaxoSmithKline, OncoGenex Pharmaceuticals, Hospira, Boehringer Ingelheim, AstraZeneca, Aveo Pharmaceuticals

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/2125996/global-and-united-states-precision-cancer-therapies-market

Segmental Analysis

The report incorporates significant sections, for example, type and end user and a variety of segments that decide the prospects of global Precision Cancer Therapies market. Each type provide data with respect to the business esteem during the conjecture time frame. The application area likewise gives information by volume and consumption during the estimate time frame. The comprehension of this segment direct the readers in perceiving the significance of variables that shape the market development.

Global Precision Cancer Therapies Market Segment By Type:

Hormone TherapyImmunotherapiesTargeted TherapyMonoclonal Antibody TherapyGene Therapy Precision Cancer Therapies

Global Precision Cancer Therapies Market Segment By Application:

HospitalsDiagnostic CentersOncology ClinicsResearch Institutes

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Precision Cancer Therapies market.

Key questions answered in the report:

For Discount, Customization in the Report Drop Your Query Here: https://www.qyresearch.com/customize-request/form/2125996/global-and-united-states-precision-cancer-therapies-market

TOC

1 Report Overview1.1 Study Scope1.2 Market Analysis by Type1.2.1 Global Precision Cancer Therapies Market Size Growth Rate by Type: 2020 VS 20261.2.2 Hormone Therapy1.2.3 Immunotherapies1.2.4 Targeted Therapy1.2.5 Monoclonal Antibody Therapy1.2.6 Gene Therapy1.3 Market by Application1.3.1 Global Precision Cancer Therapies Market Share by Application: 2020 VS 20261.3.2 Hospitals1.3.3 Diagnostic Centers1.3.4 Oncology Clinics1.3.5 Research Institutes1.4 Study Objectives1.5 Years Considered 2 Global Growth Trends2.1 Global Precision Cancer Therapies Market Perspective (2015-2026)2.2 Global Precision Cancer Therapies Growth Trends by Regions2.2.1 Precision Cancer Therapies Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Precision Cancer Therapies Historic Market Share by Regions (2015-2020)2.2.3 Precision Cancer Therapies Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Market Restraints 3 Competition Landscape by Key Players3.1 Global Top Precision Cancer Therapies Players by Market Size3.1.1 Global Top Precision Cancer Therapies Players by Revenue (2015-2020)3.1.2 Global Precision Cancer Therapies Revenue Market Share by Players (2015-2020)3.2 Global Precision Cancer Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Players Covered: Ranking by Precision Cancer Therapies Revenue3.4 Global Precision Cancer Therapies Market Concentration Ratio3.4.1 Global Precision Cancer Therapies Market Concentration Ratio (CR5 and HHI)3.4.2 Global Top 10 and Top 5 Companies by Precision Cancer Therapies Revenue in 20193.5 Key Players Precision Cancer Therapies Area Served3.6 Key Players Precision Cancer Therapies Product Solution and Service3.7 Date of Enter into Precision Cancer Therapies Market3.8 Mergers & Acquisitions, Expansion Plans 4 Precision Cancer Therapies Breakdown Data by Type (2015-2026)4.1 Global Precision Cancer Therapies Historic Market Size by Type (2015-2020)4.2 Global Precision Cancer Therapies Forecasted Market Size by Type (2021-2026) 5 Precision Cancer Therapies Breakdown Data by Application (2015-2026)5.1 Global Precision Cancer Therapies Historic Market Size by Application (2015-2020)5.2 Global Precision Cancer Therapies Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Precision Cancer Therapies Market Size (2015-2026)6.2 North America Precision Cancer Therapies Market Size by Type (2015-2020)6.3 North America Precision Cancer Therapies Market Size by Application (2015-2020)6.4 North America Precision Cancer Therapies Market Size by Country (2015-2020)6.4.1 United States6.4.2 Canada 7 Europe7.1 Europe Precision Cancer Therapies Market Size (2015-2026)7.2 Europe Precision Cancer Therapies Market Size by Type (2015-2020)7.3 Europe Precision Cancer Therapies Market Size by Application (2015-2020)7.4 Europe Precision Cancer Therapies Market Size by Country (2015-2020)7.4.1 Germany7.4.2 France7.4.3 U.K.7.4.4 Italy7.4.5 Russia7.4.6 Nordic7.4.7 Rest of Europe 8 China8.1 China Precision Cancer Therapies Market Size (2015-2026)8.2 China Precision Cancer Therapies Market Size by Type (2015-2020)8.3 China Precision Cancer Therapies Market Size by Application (2015-2020)8.4 China Precision Cancer Therapies Market Size by Region (2015-2020)8.4.1 China8.4.2 Japan8.4.3 South Korea8.4.4 Southeast Asia8.4.5 India8.4.6 Australia8.4.7 Rest of Asia-Pacific 9 Japan9.1 Japan Precision Cancer Therapies Market Size (2015-2026)9.2 Japan Precision Cancer Therapies Market Size by Type (2015-2020)9.3 Japan Precision Cancer Therapies Market Size by Application (2015-2020)9.4 Japan Precision Cancer Therapies Market Size by Country (2015-2020)9.4.1 Mexico9.4.2 Brazil 10 Southeast Asia10.1 Southeast Asia Precision Cancer Therapies Market Size (2015-2026)10.2 Southeast Asia Precision Cancer Therapies Market Size by Type (2015-2020)10.3 Southeast Asia Precision Cancer Therapies Market Size by Application (2015-2020)10.4 Southeast Asia Precision Cancer Therapies Market Size by Country (2015-2020)10.4.1 Turkey10.4.2 Saudi Arabia10.4.3 UAE10.4.4 Rest of Middle East & Africa 11 Key Players Profiles11.1 Abbott Laboratories11.1.1 Abbott Laboratories Company Details11.1.2 Abbott Laboratories Business Overview11.1.3 Abbott Laboratories Precision Cancer Therapies Introduction11.1.4 Abbott Laboratories Revenue in Precision Cancer Therapies Business (2015-2020))11.1.5 Abbott Laboratories Recent Development11.2 Bayer HealthCare11.2.1 Bayer HealthCare Company Details11.2.2 Bayer HealthCare Business Overview11.2.3 Bayer HealthCare Precision Cancer Therapies Introduction11.2.4 Bayer HealthCare Revenue in Precision Cancer Therapies Business (2015-2020)11.2.5 Bayer HealthCare Recent Development11.3 GlaxoSmithKline11.3.1 GlaxoSmithKline Company Details11.3.2 GlaxoSmithKline Business Overview11.3.3 GlaxoSmithKline Precision Cancer Therapies Introduction11.3.4 GlaxoSmithKline Revenue in Precision Cancer Therapies Business (2015-2020)11.3.5 GlaxoSmithKline Recent Development11.4 OncoGenex Pharmaceuticals11.4.1 OncoGenex Pharmaceuticals Company Details11.4.2 OncoGenex Pharmaceuticals Business Overview11.4.3 OncoGenex Pharmaceuticals Precision Cancer Therapies Introduction11.4.4 OncoGenex Pharmaceuticals Revenue in Precision Cancer Therapies Business (2015-2020)11.4.5 OncoGenex Pharmaceuticals Recent Development11.5 Hospira11.5.1 Hospira Company Details11.5.2 Hospira Business Overview11.5.3 Hospira Precision Cancer Therapies Introduction11.5.4 Hospira Revenue in Precision Cancer Therapies Business (2015-2020)11.5.5 Hospira Recent Development11.6 Boehringer Ingelheim11.6.1 Boehringer Ingelheim Company Details11.6.2 Boehringer Ingelheim Business Overview11.6.3 Boehringer Ingelheim Precision Cancer Therapies Introduction11.6.4 Boehringer Ingelheim Revenue in Precision Cancer Therapies Business (2015-2020)11.6.5 Boehringer Ingelheim Recent Development11.7 AstraZeneca11.7.1 AstraZeneca Company Details11.7.2 AstraZeneca Business Overview11.7.3 AstraZeneca Precision Cancer Therapies Introduction11.7.4 AstraZeneca Revenue in Precision Cancer Therapies Business (2015-2020)11.7.5 AstraZeneca Recent Development11.8 Aveo Pharmaceuticals11.8.1 Aveo Pharmaceuticals Company Details11.8.2 Aveo Pharmaceuticals Business Overview11.8.3 Aveo Pharmaceuticals Precision Cancer Therapies Introduction11.8.4 Aveo Pharmaceuticals Revenue in Precision Cancer Therapies Business (2015-2020)11.8.5 Aveo Pharmaceuticals Recent Development 12 Analysts Viewpoints/Conclusions 13 Appendix13.1 Research Methodology13.1.1 Methodology/Research Approach13.1.2 Data Source13.2 Disclaimer13.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Original post:
Precision Cancer Therapies Market, Share, Application Analysis, Regional Outlook, Competitive Strategies & Forecast up to 2025 |, Abbott...

Catalents Redwood Bioscience subsidiary is taking the lead role in developing ADCs for Exelixis $EXEL. In one of 2 deals announced this morning, Exelixis is turning to Catalent to do the discovery work on the ADCs, which will employ their SMARTag site-specific bioconjugation platform technology using antibodies out of the biotechs pipeline.

Catalent gets $10 million upfront to trigger the deal, with Exelixis holding worldwide development rights on anything it chooses.

In a separate ADC development deal, Exelixis is turning to NBE-Therapeutics for another pact that could steer more product candidates its way. In this deal Exelixis is paying $25 million upfront to get a 2-year alliance underway.

Exelixis is pursuing both internal drug discovery and external business development approaches to build a pipeline with the potential to make a difference for patients with cancer, saidPeter Lamb, the CSO at Exelixis. John Carroll

Back in the days when investors thought there was still good business to be made in antibiotics, Spero raised a fair bit of capital: a $30 million Series A and B led by Atlas Ventures, a $51.7 million Series C led by GV, and a $77 million IPO. In 2018, they received an up to $54 million contract with BARDA too.

The market for antibiotics has since soured, but that cash has allowed Spero to get through Phase III with its lead drug. And on Tuesday they announced positive results, showing in a 1,372-person study that their oral antibiotic tebipenem was non-inferior to the approved IV antibiotic ertapenem in treating patients with complicated urinary tract infections and acute pyelonephritis.

The drug, said trial investigator Keith Kaye, will give cUTI patients a new oral option after evolving microbiotic resistance had left them with only the IV drug.

Due to the increasing prevalence of antibiotic-resistant bacteria, many patients with cUTI now receive intravenous antibiotics as their only available treatment option, Kaye, who is also director of research in the division of infectious diseases at the University of Michigan Medical School, said in a statement. The much-anticipated data from this head-to-head comparison against an IV standard-of-care carbapenem antibiotic suggest that in many instances oral, outpatient treatment of these complicated bacterial infections is a viable option.

Spero CEO Ankit Mahadevia said it would be the first oral cUTI drug approved in 26 years. The company said it plans to start a rolling NDA and complete it by the second quarter of 2021.

An approval would be a major boon to any biotech, but when it comes to antibiotics, regulatory success doesnt necessarily translate into commercial success. Melinta and Achaoegen are well proof of that. Jason Mast

A UK-based biotech is buying outright a software developer in Brooklyn, NY, in order to bring artificial intelligence to its diagnostics tools.

APIS Assay Technologies announced the acquisition of Beogenomics on Friday, hoping to use data-mining processes to identify biomarker targets in oncology, as well as inflammatory, autoimmune and infectious diseases. The technology from Beogenomics, which has been developing both on-prem and secure cloud-based data analysis solutions, will help support the launch of a new proprietary service line. APIS mainly works in R&D and diagnostics, developing new tests for the prediction, prevention, and diagnosis of disease from discovery to regulatory approval.

The companys business model focuses on three aspects: biomarker diagnostics development, molecular diagnostic contract development, and applied bioinformatics. Max Gelman

Intravacc, a Dutch vaccines company, landed an up to $9.4 million contract from NIAID to develop a vaccine for enterovirus D68, a respiratory virus that can cause paralysis and has become increasingly common in America, Europe and Asia over the last few years.

The small biotech, which also has programs for RSV, gonorrhea and of course Covid-19, will develop an inactivated virus vaccine in Vero cells. The contract is for early product selection through Phase I. Jason Mast

Read this article:
News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero - Endpoints...